Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  2 of 97 
 
CONFIDENTIAL  1 PROTOCOL APPROVAL SI GNATURES  
 

Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  3 of 97 
 
CONFIDENTIAL  2 STUDY PERSONNEL  
Sponsor Personnel 
Clinical Operations  
Name:  Courtney Wells  
Title:  Vice President, Clinical Operations  
Address:  Flamel Ireland Limited  trading under the business name Avadel Ireland  
Blanchardstown Corporate Park  
Block 10 -1, Ballycoolin 
Dublin 15  
Ireland  
Medical Director  
Name:  Jordan Dubow  , MD  
Title:  Chief Medical Officer   
Address:  Flamel Ireland Ltd trading under the business name Avadel Ireland  
 
Block 10, Unit 1, Blanchardstown Corporate Park  
Ballycoolin  
Dublin 15   
Ireland  
 
Statistician  
 

Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  4 of 97 
 
CONFIDENTIAL  CRO Personnel  
Project Manager 
Medical Monitor  
Name:  David Seiden, MD  
Title:  Senior Medical Director  
Address:   Flamel Ireland Ltd trading under the business name Avadel Ireland  
 
 

Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  5 of 97 
 
CONFIDENTIAL  Other Personnel  
Drug Supply  
Central Clinical Laboratory 
Interactive Response Technology (IRT ) 
Central Scoring Laboratory 
 

Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  7 of 97 
 
CONFIDENTIAL  to dosing will be no more than 7 days ). For subject s randomized to the active arm of the study the maximum 
duration of treatment with FT218 will be 13  weeks incorporating up- titration over a period of 8  weeks with 5  weeks 
on stable dosing at 9.0  g/night. For subject s randomized to placebo, there is no exposure to the study treatment.  
A follow -up visit will occur at least 1 week after the last dose of FT 218 or placebo (i.e. Period  4, Visit 9, Week  15, 
Day 1 [+4/-0 (i.e. a minimum of 7 days after the last on  study dose )]). Additional follow -up for safety surveillance 
and management will be done for unresolved adverse events ( AEs) as determined by the study investigator.  
Number of Subjects:  
T
reatment:  
FT218 or placebo dosing will follow a 4 period up- titration as follows: FT218 4.5 g or placebo  daily for 1 week, 
FT218 6.0 g or placebo daily for 2 weeks, FT218 7.5 g or placebo daily for 5 weeks, and FT218 9.0 g or placebo 
daily for 5 weeks. Study drug will be taken orally at bedtime . 
Study Duration:  
There will be a 3 -week screening period, a 13 -week treatment period and a 1 -week follow -up period. Total duration 
of the stu dy will be approximately 17 weeks.  
Study Population:  
Male or female subject s 16 years of age or older; documented evidence of a diagnosis of NT1  or NT2 as, in part, 
determined by an overnight PSG and next -day multiple sleep latency test ( MSLT ) with 2 or more sleep- onset rapid 
eye movement  (REM) periods  with mean sleep latency in the pathological range i.e . < 8 minutes (screening, Visit 1) 
and MWT < 11 minutes  (after 3 -week screening period) ; current continuing presence of EDS as defined by subject  
report for the last 3 months and an ESS >  10; for NT1 only, current continuing presence of cataplexy as defined by 
subject  report for the last 3 months; subject s may use concomitant stimulants, but must comply with the following: 
they must be on a stable dose of stimulants for at least 3 weeks prior to starting the screening process for this study; 
AND they must use the same stimulant regimen throughout the entire study period, including during screening a nd 
posttreatment periods.  
Primary Endpoints : 
The primary criteria that efficacy determination will be based on include:  
• Longer MWT sleep latency  
• Improvement in CGI  sleepiness scores  
• Fewer cataplexy attacks as  recorded by Sleep and Symptom Daily D iary 
Secondary /Exploratory Endpoint s: 
E
fficacy:  
Efficac y assessments include MWT, CGI , Sleep and Symptom Daily Diary, nocturnal PSG, and E SS 

Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  8 of 97 
 
CONFIDENTIAL  Safety:  
Safety assessments includ e AEs, laboratory parameters, vital s igns, physical examination, 12-lead 
electrocardiogram , Columbia -Suicide Severity Rating Scale  
Statistical Analysis : 
A mixed -effects means model with repeated measures (MMRM) will be used to analyze change f rom baseline for 
each of the co primary endpoints. Each model will include treatment, time, treatment– by time interaction, site and 
baseline score as fixed effects and subjects as random effects.  
 
The primary hypothesis tests of the efficacy of individual doses will be performed as contrasts within the mixed 
models. The hypothesis testing will proceed in the following order: first, to test hypotheses for EDS, both MWT and CGI will be examined for statistical significance for the 9.0 g dose using the  data collected during Periods 3c(i) , and 
3c(ii). If both tests are significant, NCA for the same dose will be tested. If the first test fails (either MWT or CGI 
not significant), the data for the 9.0  g dose was not able to reject the null hypothesis of equality to placebo for either 
symptom. If the fir st test is significant (both MWT and CGI significant) but the second test (NCA) fails, the dose 
has been demonstrated to exceed placebo for EDS treatment but not for cataplexy. If both tests are statistically significant, the dose has been shown to be effe ctive for EDS and cataplexy.  
If the 9.0 g dose demonstrates efficacy for both EDS and cataplexy, the same sequence of testing will be followed for the 7.5 g dose using the data collected during Periods 3 b(i) and 3b(ii). If  the 7.5 g dose demonstrates eff icacy for both 
EDS and cataplexy, the same sequence of testing will be followed for the 6 g dose using the data collected during 
Period 3a .  
Each dose will be tested in a hierarchical order starting at the 9.0 g dose level at the 2 -sided α level of 0 .05. Efficacy 
tests for MWT and for CGI within a dose need not be adjusted, since both are required for demonstrating efficacy for EDS at that dose. Efficacy tests for NCA within a dose for demonstrating efficacy for cataplexy also need not be adjusted because t he test is reached via a step down procedure. Within each step , rejection terminates all subsequent 
hypothesis tests,  which will be deemed to be nonsignificant. A strictly exploratory analysis examining 
secondary/exploratory endpoints is also proposed to provid e evidence of consistency. The type I error rate for these 
endpoints will all be tested at the α  level of 0.05. 

Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  9 of 97 
 
CONFIDENTIAL  4 TABLE OF CONTENTS  
1 Protocol Approval Signatures ....................................................................................... 2  
2 Study Personnel  .............................................................................................................. 3  
3 Synopsis  ........................................................................................................................... 6  
4 Table of Contents  ............................................................................................................ 9  
5 List of Abbreviations and Definition of Terms .......................................................... 12  
6 Introduction................................................................................................................... 15  
6.1 Scientific Background  .................................................................................................. 15  
6.1.1  Summary  ........................................................................................................ 15  
6.1.2  Disease Under Treatment  .............................................................................. 15  
6.1.2.1  Symptoms of Narcolepsy ............................................................................... 16  
6.1.2.2  Pharmacologic Treatment Options  ................................................................ 17  
6.2 Background to FT218 Controlled- Release Technology  ............................................ 18  
6.2.1  Sodium Oxybate Drug Metabolism and Pharmacokinetics ........................... 18  
6.2.2  FT218 Development ...................................................................................... 19  
6.3 Preclinical Experience and Animal Models  ............................................................... 19  
 ..................... 20  
6.5 Study Rationale ............................................................................................................. 24  
6.6 Potential Risks and Benefits  ........................................................................................ 25  
7 Study Objectives  ........................................................................................................... 28  
7.1 Primary Objective  ........................................................................................................ 28  
7.2 Secondary/Exploratory Objectives ............................................................................. 28  
7.3 Safety Objective  ............................................................................................................ 28  
8 Investigational Plan ...................................................................................................... 29  
8.1 Overall Study Design and Plan: Description  .............................................................. 29  
8.1.1  Study Design .................................................................................................. 30  
  ................................ ............................................... 31  
8.2 Discussion of Study Design  .......................................................................................... 35  
8.3 Selection of Study Population ...................................................................................... 35  
8.3.1  Number of Planned Subjects ......................................................................... 35  
8.3.2  Inclusion Criteria  ........................................................................................... 35  
8.3.3  Exclusion Criteria  .......................................................................................... 36  

Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  10 of 97 
 
CONFIDENTIAL  8.3.4  Removal of Subjects From Therapy or Assessments .................................... 38  
8.3.4.1  Pregnancy  ...................................................................................................... 39  
8.4 Investigational Product ................................................................................................ 40  
8.4.1  Investigational Products Administered  .......................................................... 40  
8.4.1.1  Definition of a Schedule I/Controlled Drug Substance ................................. 40  
8.4.1.2  FT218 Study Drug Risk Management  ........................................................... 40  
8.4.1.3  Specification for Managing Controlled Substances ...................................... 41  
8.4.1.4  Drug Accountability ...................................................................................... 41  
8.4.1.5  FT218/Placebo ............................................................................................... 42  
8.4.2  Identity of Investigational Products ............................................................... 43  
8.4.3  Packaging and Labelling  ................................................................................ 43  
8.4.4  Method of Assigning Subjects to Treatment Groups .................................... 44  
8.4.5  Selection of Doses in the Study ..................................................................... 45  
8.4.6  Selection and Timing of Dose for Each Subject ............................................ 45  
8.4.7  Study Blinding and Unblinding Procedures .................................................. 46  
8.4.8  Prior and Concomitant Therapy ..................................................................... 47  
8.4.8.1  Prohibited Medication/Therapy ..................................................................... 47  
8.4.9  Treatment Compliance  ................................................................................... 48  
9 Timing of Study Procedures  ........................................................................................ 49  
9.1 Pre-treatment – Periods 1 and 2 .................................................................................. 50  
9.1.1  Period 1: Visit 1 (Week -3, Day 1) Screening and Assessment .................... 50  
9.1.2  Period 2: Visit 2 (Week -1, Day 7) Baseline Visit ........................................ 51  
9.1.2.1  Central Scoring Laboratory: PSG and MWT (+ 2 Days for results) ............. 52  
9.1.2.2  Randomization ............................................................................................... 52  
9.2 Treatment Period – Period 3 (Dose Titration and Stabilization) ............................. 53  
9.2.1  Period 3a: Visit 3 (Week 1 , Day 1) Dose Titration to 6.0 g/Night ................ 53  
9.2.2  Period 3b(i): Visit 4 (Week 3, Day 7) Dose Titration to 7.5 g /Night ........... 54  
9.2.3  Period 3b(ii): Visit 5 (Week 6, Day 1) 7.5 g/Night ....................................... 55  
9.2.4  Period 3c(i): Visit 6 (Week 8, Day 7) Dose Titration to 9.0 g/Night, 
Stabilization  ................................................................................................... 56  
9.2.5  Period 3c(ii): Visit 7 (Week 11, Day 1) Stabilization ................................... 57  
9.2.6  Period 3c(iii) Visit 8 (Week 13, Day 7) End of Study (EOS) ....................... 58  
9.3 Follow- up Period – Period 4  ........................................................................................ 59  
9.3.1  Period 4: Visit 9 (Week 15, Day 1) Follow-up .............................................. 59  
9.4 Unscheduled Visits  ........................................................................................................ 60  
9.5 Duration of Treatment  ................................................................................................. 61  
10 Effic acy and Safety Variables ...................................................................................... 61  
10.1  Efficacy and Safety Measurements Assessed  ............................................................. 61  
  61 

Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  11 of 97 
 
CONFIDENTIAL  10.1.1.1  Maintenance of Wakefulness Test  ................................................................. 61  
10.1.1.2  Clinical Global Impression of Sleepiness  ...................................................... 61  
10.1.1.3  Sleep and Symptoms Daily Diary .................................................................. 61  
 .............. 62  
10.1.1.5  Epworth Sleepiness Scale .............................................................................. 62  
10.1.2  Safety Assessments  ........................................................................................ 62  
10.1.2.1  Adverse Events  .............................................................................................. 62  
10.1.2.2  Clinical Laboratory Evaluation ...................................................................... 69  
10.1.2.3  Vital Signs  ..................................................................................................... 70  
10.1.2.4  Physical Examination  .................................................................................... 70  
10.1.2.5  Electrocardiogram  .......................................................................................... 70  
10.1.3  Appropriateness of Measurements  ................................................................ 70  
11 Statistical Methods  ........................................................................................................ 71  
11.1  Stati stical and Analytical Plans ................................................................................... 71  
11.2  Definition of the Analysis Populations ........................................................................ 71  
11.2.1  Determination of Sample Size  ....................................................................... 71  
11.2.2  Randomization and Blinding ......................................................................... 71  
11.2.3  Interim Analysis and Unblinding ................................................................... 72  
11.2.4  Data and Safety Monitoring Board ................................................................ 72  
11.3  Analysis Sets .................................................................................................................. 72  
11.3.1  Intent- to-Treat (ITT) Population .................................................................... 72  
11.3.2  Per Protocol (PP) Population ......................................................................... 72  
11.3.2.1  Safety (S) Population ..................................................................................... 72  
11.4  Description of Statistical Analysis  ............................................................................... 72  
11.4.1  General Considerations .................................................................................. 73  
11.4.2  Use of Analysis Sets  ...................................................................................... 73  
11.4.3  Analysis of Subgroups ................................................................................... 73  
 ................................ ............................................. 73  
11.5  Subject Disposition  ....................................................................................................... 73  
11.6  Demographic and Other Baseline Characteristics  .................................................... 73  
11.7  Medical History  ............................................................................................................. 73  
11.8  Study Drug Exposure and Compliance  ...................................................................... 74  
11.9  Efficacy Analysis ........................................................................................................... 74  
11.9.1  Description of Primary Endpoints ................................................................. 74  
11.9.1.1  Primary Analysis  ........................................................................................... 74  
11.9.1.2  Sequential Testing Approach for Comparing FT219 and Placebo ................ 74  
 .................................. 75  
......................... ......... 75  
 .................................. 76  

Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  12 of 97 
 
CONFIDENTIAL  11.10  Safety Analysis .............................................................................................................. 76  
11.10.1.1  Laboratory Data ............................................................................................. 76  
11.11  Data and Safety Monitoring Board ............................................................................. 76  
11.12  Central Scoring Laboratory ........................................................................................ 77  
11.13  Protocol Deviations ....................................................................................................... 77  
12 Quality Assurance and Quality Control ..................................................................... 77  
12.1  Audit and Inspection  .................................................................................................... 77  
12.2  Mon itoring  ..................................................................................................................... 77  
12.3  Data Management and Coding .................................................................................... 78  
13 Records and Supplies  ................................................................................................... 79  
13.1  Finan cing and Insurance  .............................................................................................. 79  
14 Ethics  .............................................................................................................................. 80  
14.1  Independent Ethics Committee or Institutional Review Board  ............................... 80  
14.2  Regulatory Authorities ................................................................................................. 80  
14.3  Ethical Conduct of the Study  ....................................................................................... 80  
14.4  Informed Consent and Assent  ..................................................................................... 80  
14.5  Subject Confidentiality  ................................................................................................. 81  
15 Reporting and Publication, Including Archiving  ...................................................... 82  
16 References  ...................................................................................................................... 83  
17 Appendices ..................................................................................................................... 85  
17.1  Investigator Signature Page ......................................................................................... 86  
17.2  Study Drug Kit Dispensing  .......................................................................................... 87  
 ................................ ................................................. 88  
17.4  Columbia -Suicide Severity Rating Scale (C -SSRS) – Since Last Visit 
Version  92  
17.5  Columbia -Suicide Severity Rating Scale (C -SSRS) – Baseline/Screening 
Version  93  
17.6  CGI -Severity (CGI -S) / CGI -Improvement (CGI -I) ................................................. 96  
17.7  Epworth Sleepiness Scale  ............................................................................................. 97  
5 LIST OF ABBREVIATIONS AND DEFINITION OF TERMS  

Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  13 of 97 
 
CONFIDENTIAL  LIST OF ABBREVIATIONS  
AE adverse event  
AUC  area under the curve  
BMI  body mass index  
BP blood pressure  
CGI clinical  global impression  
CNS  central nervous system  
Cmax maximum concentration  
CRO  contract research organ ization 
C-SSRS Columbia -Suicide Severity Rating Scale  
DNS  disturbed nocturnal sleep  
DSMB  Data S afety Monitoring Board 
ECG  electrocardiogram  
eCRF  electronic case report form  
EDC  electronic data capture  
EDS  excessive daytime sleepiness  
EMA  European Medicines Agency  
ESS Epwor th Sleepiness Scale 
FDA  United States Food and Drug Administration  
FT218  sodium oxybate  for extended -release oral suspension  
GABA  gamma -aminobutyric acid  
cGCP  current Good Clinical Practice  
GHB  gamma -hydroxybutyric acid (sodium oxybate)  
GI gastrointestinal  
HBs Ag hepatitis B surface antigen  
HCVAb  hepatitis C virus antibody  
HH hypnagogic hallucinations  
HLA  human leukocytes antigen  
ICF informed consent form  
ICH International Co uncil for Harmoni sation  
IEC independent ethics committee  
IRB institutional review board 
IRT interactive response technology  
ITT intent -to-treat 
MAOI  monoamine oxidase inhibitor  
MedDRA  Medical Dictionary for Regulatory Activities  
MSLT  multiple sleep latency test  
MWT  maintenance of wakefulness test  
n number of subjects with an observation  
N number of subjects in the dataset or population  
NCA  number of cataplexy attacks  
NT1 type 1 narcolepsy  
NT2 type 2 narcolepsy  
PI principal investigator  
PK pharmacokinetic  
PP per protocol  
PSG polysomnography  
REM  rapid eye movement  
SAE  serious adverse event  
SOC  system organ class  
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  14 of 97 
 
CONFIDENTIAL  SOREM  Sleep -onset REM  
SNRI  serotonin and norepinephrine re -uptake inhibitors  
SP sleep paralysis  
SSRI  selective serotonin re -uptake inhibitors  
SUSAR  suspected unexpected serious adverse reaction  
t1/2 half-life 
TCA  tricyclic antidepressants  
Tmax time to maximum concentration  
US United States  
VAS  visual analog scale  
WHO  World Health Organiz ation  
 
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  15 of 97 
 
CONFIDENTIAL  6 INTRODUCTION 
6.1 Scientific Background  
6.1.1 Summary  
Sodium oxybate , also known as gamma -hydroxybutyric acid (GHB), was discovered in 1960. 
Sodium oxybate (GHB) is a metabolite of γ -aminobutyric acid (GABA) which is synthesized by 
neurons in the brain and functions as a neurotransmitter. Sodium oxybate is a central nervous 
system (CNS) depressant and produces dose -dependent sedation and anesthesia in laboratory 
animals. Sodium oxybate is currently indicated for the treatment of cataplexy and excessive daytime sleepiness (EDS) in subject s with narcolepsy at doses up to 9.0 g/night. In 2002, the US 
Food and Drug Administration ( FDA ) approved Xyrem
® (sodium oxybate) oral solution as an 
orphan drug for the treatment of cataplexy in adult subject s with narcolepsy. In 2005, this 
approval was extended to the treatment of EDS for adults with narcolepsy. In Europe, sodium oxybate was granted Orphan Drug Designation in February 2003 (however, the orphan 
designation request has since been withdrawn), and the European Comm ission issued a decision 
in 2005 for its marketing authorization for the treatment of cataplexy in adult subject s with 
narcolepsy that was extended in 2007 to treating EDS in adults with narcolepsy.  
As part of a recent meeting for the narcolepsy community initiated by the Food and Drug 
Administration ( FDA ), the FDA inquired “Assuming there is no complete cure for your 
condition, what specific things would you look for in an ideal therapy for your condition?” In an 
interim report circulated from the patient advocacy community, Unite Narcolepsy, summarizing 
the results from a patient survey with 1350 responses in preparation for the FDA meeting, the 
first statement responding to the FDA’s question was an excerpt from a patient response stating 
“A drug that would provide consistent and adequate control of the daytime sleepiness without the 
hard crash and one that would require 1 dose taken at bedtime resulting in 8 hours of restorative 
sleep ”.
1 
Flamel Technologies has developed a drug delivery technology designed to extend and/or delay 
the absorption of a drug in order to control its pharmacokinetic (PK) profile. Based on this proprietary controlled- releas e delivery technology, Micropump
®, Flamel Technologies has 
developed a new formulation of sodium oxybate which is more convenient for the subject  in that 
it is dosed only once (i .e. at bedtime). The once nightly dosing is an improvement beyond the 
current approved dosing regimen for Xyrem that requires narcolepsy subject s to wake up in the 
middle of the night to take a second dose.  
6.1.2 Disease Under Treatment  
Narcolepsy is a chronic, life -disrupting neurologically- based sleep disorder characterized by 5 
major symptoms, EDS, cataplexy, hypnagogic hallucinations  (HH) , sleep paralysis  (SP) , and 
disturbed nocturnal sleep  (DNS) . Narcolepsy is associated with increased morbidity,2,3 increased 
mortality,4 and reduced quality of life.5 In addition, there are significant social6,7 and economic8,9 
impacts for subject s with narcolepsy, their families, and the healthcare system.10 
Narcolepsy is currently dichotomized by the International Classification of Sleep Disorder s-3 as 
either type 1 narcolepsy (NT1) or t ype 2 n arcolepsy (NT2).11 Type 1 narcolepsy is diagnosed by 
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  16 of 97 
 
CONFIDENTIAL  the presence of EDS, cataplexy, a Multiple Sleep Latency Test (MSLT) indicating 2 or more 
sleep -onset rapid eye movement ( REM ) periods (SOREMs) and a mean sleep latency in the 
pathological ra nge (i .e. < 8 minutes), and/or low hypocretin ( ≤ 110 pg/mL). Type 2 narcolepsy is 
diagnosed in the absence of cataplexy and when hypocretin levels are greater than 110 pg/mL, but the other diagnostic criteria for NT1 are met, including EDS, a MSLT indicating 2 or more 
SOREM s and a mean sleep latency in the pathological range ( i.e. < 8 minutes), as well as the 
absence of another sleep disorder  that better explains the EDS.  
Narcolepsy is a rare disease, with 65,000 of the approximately 100,000 to 200,000 cases 
currently diagnosed in the US . Type 1 narcolepsy or narcolepsy with cataple xy is estimated to 
have a prevalence of 25 to 50 per 100,000 people and an incidence of 0.74 per 100,000 person -
years internationally.
12,13,14 Evidence indicates that NT1 is caused by the loss of hypocretin (also 
called orexin) cells in the hypothalamus. Thus, the best biological marker for NT1 is the reduction or complete deficiency of hypocretin in the cerebros pinal fluid . 
Over 92% of Caucasian subject s with NT1 carry the  human leukocyt es antigen 
(HLA) -DQB1*06:02, while HLA -DQB1*06:03 allele confers a strong protection.
15,16 The 
association with specific HLA alleles has allowed for the hypothesis that narcolepsy is an autoimmune disease, and progress has been made further substantiating an autoimmune origin for N T1 including: 1) anti -TRIBBLES -2 antibodies
17, 2) elevated antistreptolysin O titers 
discovered close to disease onset18, and 3) the association with a polymorphism of T -cell 
receptor alpha gene and a polymorphism of the purinergic receptor P2RY11 gene.19 However, 
the mechanism for this autoimmune process remains unknown. 
6.1.2.1 Symptoms of Narcolepsy 
The hallmark symptom of narcolepsy is EDS, and is hence required for the diagnosis of 
narcolep sy. It is also the most troublesome symptom and the one for which subject s most 
commonly seek treatment. E xcessive daytime sleepiness  is defined as the inability to stay awake 
and alert during the day, resulting in periods of involuntary sleep episodes or unintended lapses into “drowsiness” duri ng activities of daily living. In narcolepsy, EDS can exist despite adeq uate 
nighttime sleep, is not caused by another disease or condition which better explains the EDS, or persists when other conditions known to also cause EDS are treated. The chronic and severe nature of EDS predisposes these subject s to deficits in multiple areas of functioning. When 
alertness is compromised (i.e . sleepiness is pervasive), performance may be diminished across a 
variety of cognitive functions, work related safety may be compromised, and productivity and 
overall quality of life may suffer. It is possible the performance deficits may precipitate reduced 
patient -reported quality of life and difficulty with achievement in work and/or school. Beyond 
this, the sleepiness can be so omnipresent as to cause subject s to socially withdraw, making 
relationships with family and frien ds difficult to maintain and potentially strained.  
Cataplexy, in the presence of EDS, is suggestive of NT1 and an indication for objective testing to 
confirm the diagnosis. Cataplexy is defined as a sudden muscle weakness episode and can affect 
a few muscl es (for example, facial muscles) or all skeletal muscles at once. As a result of the 
muscle weakness, subject s momentarily have head nodding from weakness in the neck muscles, 
sagging of the jaw, buckling of the knees, dropping of objects from hands, and/or dysarthria or 
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  17 of 97 
 
CONFIDENTIAL  inability to speak during the episode. Sometimes they may slump or fall forward onto the 
ground, either all at once or more gradually.  
Cataplexy attacks are typically brief, on average, lasting fro m milliseconds to 1  to 2 minutes. 
Cataplex y is typically triggered by emotions, most often by telling or hearing a joke, laughing, or 
becoming angry. These emotions have been combined to successfully identify cataplexy among 
cases and lack of cataplexy among controls with remarkable specificity. F or those with 
cataplexy, though, a wide range of emotions may be triggers, including surprise, rage, fear, 
enjoyment, love, accomplishment, and/or satisfaction from accomplishment ( e.g. winning in an 
athletic competition). Sometimes the emotions cause cata plexy in situations with a social 
component, meaning that others are involved in eliciting the emotion, including other family members, friends, children, and/or pets. At initial presentation and close to symptom onset, and especially in children and teenagers, the onset of a cataplexy attack may not be precipitated by an emotional trigger and can happen almost spontaneously, termed atypical cataplexy.    
Cataplexy is the most narcolepsy specific symptom, and it is unclear as to how and why the frequency or  severity varies across subject s and may or may not change over time. Cataplexy is 
hypothesized to be a manifestation of REM  atonia in waking. Thus when these episodes last for 
longer per iods of time they evolve into REM sleep episode s and are perceived by the subject  as 
sleep episode s with no memory of the cataplexy which preceded them. The onset of cataplexy 
typically  occurs after the onset of EDS. Less frequently it can occur years after the EDS. Aside 
from the emotional triggers for cataplexy attacks, w ithdrawal from REM suppressing drugs may 
also cause them.  
Additional symptoms completing the narcolepsy pentad include HH (vivid dreams at sleep onset 
or offset that are more often associated with negative emotions), and SP ( feeling unable to move 
the body during transition periods of sleep). These may occur simultaneously and are oft en 
frightening to the subject . More specific for narcolepsy is their occurrence at sleep onset. Like 
cataplexy, SP and HH are REM related phenomena. Thus, experiencing them at sleep onset is rare in the general population. Experiencing them at sleep offset may simply be an awakening from REM. Thus, their occurrence at sleep offset is seen in the general population. 
Disturbed nocturnal sleep (DNS) is the second most common symptom among narcolepsy 
subject s.
20 The DNS observed in narcolepsy is distinct from that seen in insomnia. While 
subject s with insomnia have difficulty falling asleep at the beginning of the night and after 
nocturnal awakening, subject s with narcolepsy fall asleep faster than insomniacs and even the 
general population. Disturbed nocturnal sleep in narcolepsy is characterize d by frequent brief 
awakenings or shifts to lighter stages of sleep during the sleep period that are transient, with increased Stage 1 sleep, and reduced deeper stages of sleep. Often this leaves subject s feeling 
poorly rested or that their sleep was not r efreshing. The contribution of DNS  to the EDS in 
narcolepsy is not well understood.  
6.1.2.2 Pharmacologic Treatment O ptions  
Treatments for narcolepsy aim to relieve its symptoms, and are not directed towards any target 
known to be in the pathophysiological pathw ay of the disease.  Thus, treatment includes 
stimulants to relieve EDS, sodium oxybate for EDS and cataplexy, and REM suppressing drugs 
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  18 of 97 
 
CONFIDENTIAL  including tricyclic antidepressants (TCAs), selective serotonin re -uptake inhibitors (SSRIs), or 
monoamine oxidase inhibi tors (MAOIs) to relieve cataplexy as well as HH and SP. The severity 
of the symptoms can vary greatly from one person to another, and thus the response to any given 
medication is similarly varied from subject  to subject . 
Stimulants improve EDS in narcoleps y (eg, modafinil, armodafinil, methylphenidate, 
dextroamphetamine, or methamphetamine).21,22 In diagnosed subject s, modafinil, armodafinil, 
and methylphenidate are often prescribed first to reduce EDS. Dextroamphetamine and methamphetamine are potential alternatives for subject s who do not res pond satisfactorily to the 
“front line” stimulant options. Some subject s may need a combination of drugs or a mixture of 
short - and longer -acting medications for optimal treatment. This evidences the fact that while 
stimulants improve EDS they do not norm alize it. This is confirmed by patient reports in 
systematic studies.
23, 24 
Potent REM suppressing drugs ( i.e. SSRIs, TCAs and MAOIs) are used to treat cataplexy as well 
as HH and SP; however, the efficacy of these drugs in treating cataplexy has not been established in controlled clinical studies , but is based on experience from  off-label use. Sodium oxybate 
(GHB ), was approved by the FDA  as Xyrem  in 2002 for the treatment of cataplexy in adults with 
NT1. Subsequently, the improvement in daytime sleepiness led to a label extension to treat EDS in both types of narcolepsy. Sodium oxybate is administered in 2 divide d doses at night, taken a t 
bedtime and approximately 2.5 to 4 hours later. D isturbed nocturnal sleep is a symptom of 
narcolepsy that does not currently have any drugs indicated for its treatment.  
Despite the number of therapeutic options, narcolepsy medic ations are often not fully effective. 
It has been noted that there are drawbacks to the treatment regim en that can hinder compliance.  
Thus there remains a need for new agents. The twice nightly dosing regimen for Xyrem  is 
inconvenient for subject s. With th e availability of its drug delivery technology that allows for an 
extended release of drugs, Flamel Technologies has developed a new formulation of sodium 
oxybate, under investigation in this clinical study, with the objective to provide a therapy that is 
dosed only once at bedtime and provides subject s with the same level of efficacy and safety as 
the current twice nightly therapy.  
6.2 Background to FT218 Controlled -Release Technology  
6.2.1 Sodium Oxybate Drug Metabolism and Pharmacokinetics  
The active ingredient o f FT218, sodium oxybate, is a CNS  depres sant. Sodium oxybate is the 
nonproprietary name for the sodium salt of GHB, a metabolite of GABA, which is synthesized 
and accumulated by neurons in the brain. It is present at μM concentrations in all brain regions 
investigated as well as in several peripheral org ans, particularly in the gastrointestinal (GI) 
system. Sodium oxybate is rapidly absorbed after oral administration with an absolute bioavailability of about 25% due to a large hepatic first pass effect. Pharmacokinetics are nonlinear, following oral administration, the plasma levels of sodium oxybate increase more than 
proportionally with increasing dose. The clearance of sodium oxybate is almost entirely by 
biotransformation to carbon dioxide, which is then eliminated by expiration. On average, less 
than 5% of unchanged drug appears in human urine within 6 to 8 hours after dosing. Fecal 
excretion is negligible.  
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  19 of 97 
 
CONFIDENTIAL  The efficacy and safety profiles of the currently marketed formulation of sodium oxybate, 
Xyrem, a re well characterized. The molecular formula of FT218 active ingredient is C 4H7Na0 3 
with molecular weight of 126.1. The chemical name is s odium 4- hydroxybutanoate.  
 
6.2.2 FT218 Development  
Flamel has developed an extended -release oral suspension formulation of sodium oxybate, with 
the same active ingredient as the currently available and marketed product of sodium oxybate, 
Xyrem (NDA 021196) for treating EDS and cataplexy in subject s with narcolepsy. Flamel’s 
formu lation provides for a n extended -release of the active ingredient by utilizing its proprietary 
technology, Micropump. This technology is the same as that used for the marketed drug product Coreg CR
® (carvedilol, NDA 022012) for the treatment of hypertension, left ventricular 
dysfunction, and mild to severe heart failure. Coreg CR  has been marketed in the US  since 2007. 
The Micropump technology is designed to extend and/or delay the absorption of drugs, which 
allows more controlled regulation of the drug’s PK  profile. FT218 is intended to provide a 
formulation of sodium oxybate which is dosed once at bedtime rather than the twice nightly dosing regimen of Xyrem which is taken at bedtime and then again 2.5 to 4 hours later. It is proposed that the FT218 once ni ghtly dosing regimen represents an improved therapeutic option 
for subject s.   
The FT218 drug product is composed of both immediate and modified release micro particles, 
where release is a function of time and pH. The formulation also contains a range of suspending agents and an acid buffer which impart both physical and chemical stability to the reconstituted aqueous suspension before administration. All FT218 formulation excipients are adequately qualified for use at the doses of the FT218 product.  
6.3 Precli nical Experience and Animal Models  
No nonclinical studies have been conducted during FT218 development. The reason was 2- fold, 
firstly, animal species are not relevant to evaluate the PK  profile of FT218 due to the specific 
nature of the product’s release mechanism and the differences between animal and human GI 
physiology. Se condly, the availability of nonclinical data on sod ium oxybate, from the Xyrem 
nonclinical revie ws by the  FDA in 2002, the European Medicines Agency (EMA) in 2005, and 
by Health Canada  in 2006 with later updates and assessment reports on intended extension of 
use.  
At pharmacological doses sodium oxybate acts as a CNS depressant. Sodium oxybate was found to have an affinity for 2 receptors in the brain, a GHB specific receptor and a GAB A-B receptor. 
Sodium oxybate appears to have no affinity for the GABA -A receptor.  

Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  20 of 97 
 
CONFIDENTIAL  The submitted nonclinical data for Xyrem showed the safety of sodium oxybate in animal 
models, and it demonstrated transient drops in blood pressure (BP) as well as bradycardia. This was however limited to the species evaluated. Induced sleep from sodium oxybate, in both animal and man was found not to be accompanied by a decrease in oxygen consumption. The respiratory center remains sensitive to carbon dioxide although the slow- wave/delta sleep is 
enhanced. A slight drop in body temperature was observed in rats given sodium oxybate. Some animal studies report apparent epileptiform (epileptic/seizure -like) electroencephalography  
changes which have not been observed in human studies following sodium oxybate 
administration.  
Pharmacodynamic interaction during the concomitant administration of sodium oxybate with 
CNS depressants such as benzodiazepines, barbiturates, and alcohol may result in additive increases in sedation and respiratory adverse effects. They are thus contraindicated.  

Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  21 of 97 
 
CONFIDENTIAL  

Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  22 of 97 
 
CONFIDENTIAL  

Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  23 of 97 
 
CONFIDENTIAL  

Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  24 of 97 
 
CONFIDENTIAL  6.5
 Study Rationale 
Sodium oxybate has shown significant efficacy for EDS and cataplexy in the treatment of NT1 
and NT2. Flamel Technologies is proposing a new sodium oxybate drug product, FT218, which utilizes the company’s proprietary Micropump technology. The proposed innovation is clinically relevant as the current marketed product, Xyrem, has to be taken twice during the night, 2.5 to 4 hours apart, which is a li mitation.  
The FT218 Phase 1 study (study PKFT218-1301) confirmed the expected PK properties of the FT218 formulation i.e.  a release of the drug over at least 6 hours, a lower C
max and a residual 
plasma level at 8 hours after intake not significantly different than the reference. Overall, under the hypothesis of a PK exposure- clinical effect relationship, this study confirmed that FT218 will 
be as safe as the reference marketed prod uct. The forced up-titration design of this study is 
expected to be particularly informative, allowing observations of efficacy and safety at 6.0, 7.5, and 9g doses. Three therapeutic doses will be tested under forced up- titration ( 6.0, 7.5, and 9.0 g) 
since no concentration/response relationship is known. The study allows for forced dose 
increments at fixed times from 4.5 g/night followed by 1.5 g/night increments until the final 9.0 g dose is reached. Subjects will remain on the 4.5 g dose for 1 week, the 6.0 g dose for 2 weeks, the 7.5 g dose for 5 weeks and the 9.0 g dose for 5 weeks. Evaluations for efficacy and safety for 6.0, 7.5, and 9.0 g will be done ove r a 12 -week period (total of 13 weeks on study drug) relative 
to the placebo group.  
The up- titration is based on the dosage schedule recognized as safe with Xyrem. A full efficacy 
assessment will occur for the 6.0 g/night dose after 3 weeks on study drug (including a titration 
from 4.5 g/night for the first week followed by 2 weeks at 6.0 g/night). The 7.5 g full efficacy 

Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  25 of 97 
 
CONFIDENTIAL  assessment will occur after 8 weeks on study drug (including 1 week at 4.5 g and 2 weeks at 6.0 
g). A final titration occurs to maximum dose (i.e. 9.0 g). A full efficacy assessment will be done following 5 weeks on the final dose (that is following a total of 13 weeks on medication) relative to the placebo group. During both the 7.5 g and the 9.0 g 5- week treatment a partial efficacy 
assessment  will be carried out af ter 
2 weeks on the respective doses. 
The selected FT218 doses for the current study match the therapeutic dose range recognized as 
safe and effective for the reference drug product, Xyrem. All FT218 doses (6.0, 7.5, and 9.0 g) were selected for their safet y and efficacy profile in treating subject s with narcolepsy based on 
previous studies with sodium oxybate. In addition, results from the Phase 1 PKFT218-1301 study indicated that the study formulation is safe at 4.5, 6.0, and 7.5 g/night in healthy volunteers. Given the PK characteristics of the current formulation of FT218, the proposed doses are not anticipated to be associated with any safety concerns.  
Full safety and efficacy of FT218 will be evaluated in this clinical study. A double-blind, 
placebo -controlled randomized methodology has been identified as the optimal design to support 
efficacy and safety evaluation.  
This FT218 clinical study has been designed to ensure conduct and analysis according to sound 
scientific principles to achieve study objec tives. Placebo has been selected as the choice for the 
control group, as this will optimize inferences drawn from the study. It will provide for an undiluted evaluation of total pharmacological and treatment effect ( i.e., study drug versus 
disease). In add ition, this approach lends itself to a smaller sample size requirement.   
Randomization will provide a means of assuring comparability of test groups  in expectation  and 
minimiz e selection bias, and the double- blind method will minimiz e risk of biased study 
outcomes. The set study enroll ment criteria, screenin g and baseline assessment, wash out 
requirements and on- treatment conduct and assessment will minimize variables that could 
influence outcome except for that of the study drug being evaluated. The proposed study population as defined by the enrol lment criteria will ensure a consistent sample and one that is 
largely representative of the broader patient population with NT1 and NT2. Combined these will enhance the generalizability of the study results.   
The safety, dignity, and rights of study subject s predominate. It is thought that the proposed 
study design does not raise any ethical issues. The study is of appropriate duration for a chronic 
condition, there are no life-limiting effects from placebo, and study subjects can withdraw from the study at any time. This latter option will be made explicit during the informed consent process.  
6.6 Potential Risks and Benefits  
Based on early studies of FT218, it is possible to predict some of the discomforts and risks. The 
data suggest that the potential risks of FT218 are likely to be manageable and will be monitored like Xyrem. Clinical studies with Xyrem have yielded detailed information of its safety profile. Xyrem is approved by the FDA in the US and EMA for the treatment of subject s with 
narcolepsy. The potential risks of FT218 from PK studies in humans have been discussed in the 

Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  26 of 97 
 
CONFIDENTIAL  summary from the Phase 1 safety study (discussed in Section 6.3) and to date are consistent with 
and similar to what has been previously reported with sodium oxybate.  
Clinical safety of Xyrem has been established and forms the basis for the FT218 safety plan. All 
causality and treatment- related events for Xyrem include: abdominal pain, diarrhoea, nausea, 
vomiting, fatigue, peripheral oedema, anorexia, dizziness, headache, abnormal dreams, confused 
state, nightmare, sleep walking and enuresis. The most commonly identi fied AEs  for sodium 
oxybate are nausea, dizziness and headache. In terms of AEs  where there was a dose response 
relationship, these AEs  included nausea, vomiting, paraesthesia, disorientation, irritability, 
disturbance in attention, feeling drunk, sleepwal king and enuresis. These events are most 
pronounced at the higher, 9.0 g dose, and in some ca ses related to the 7.5 g dose. The up- titration 
methods, as used with Xyrem, to maximum dose, are thus appropriate to establish safety and 
tolerability in study su bjects who will participate in this clinical study.  
The safety profile of Xyrem is thus well characterized. The safety profile, as described in the Xyrem approved labelling supports the safety of the FT218 study formulation. In addition, all necessary pre cautions and warnings relate d to subject self -care and self -monitoring for any signs 
and symptoms of respiratory or CNS depression, alcohol consumption, contraindicated medications, driving and use of heavy machinery apply to F T218. The proprietary extended-
release oral suspension  technology used for FT218 is well established. The technology is the 
same as that used for the marketed product Coreg CR (carvedilol, NDA 022012) for the treatment of hypertension, left ventricular dysfunction and mild to severe heart failure. T his has 
been marketed in the US  since 2007.  
In addition to clinical safety and efficacy, consideration to the risk- benefit profile as it relates to 
abuse potential warrants careful consideration. Flamel Technologies has considered the wider 
risks of abuse potential. Data relating to drug abuse potential of illicit forms of GHB, sodium oxybate and related products with abuse potential, underwent extensive review by the W orld 
Health Organization (WHO) E xpert Committee on drug dependence in 2012. At this meeting it 
was acknowledged that most GHB for abuse originates from clandestine manufacture and there was consensus on the associated narrow margin for safety. Outputs from Xyrem’s  risk evaluation 
and mitigation strategies  post marketing  data were also evaluated. The finding showed minimal 
abuse or diversion of Xyrem. Clinical study supply and distribution methods for FT218 will adhere to regulatory and current Good Clinical Practice ( cGCP) requirements. Within the clinical 
study framewor k a “closed system” of supply and distribution will be employed. Enhancement of 
this approach will be facilitated through implementation of study specific strateg ies to augment 
safety and mitigate abuse potential.  
FT218 will provide a beneficial and altern ative therapeutic strategy for subject s with narcolepsy. 
Sodium oxybate has a well characterized safety profile and is a known and establ ished 
therapeutic choice among  physicians for treating subject s with NT1 and NT2. Physicians are 
largely familiar with its use and application in clinical practice and the potential benefits of the sodium oxybate have been documented in the literature. The burden for the subject  enrolled in 
this study is concentrated but not significantly greater than that which they exper ience during 
routine clinical practice for disease management.  
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  27 of 97 
 
CONFIDENTIAL  This study will be conducted in compliance with the protocol, GCP, applicable regulatory 
requirements, and International C ouncil for Harmonisation (ICH) guidelines. Cognizant of 
FT218’s designation as a Schedule I /Controlled  Drug and associated safety risk profile and abuse 
potential, study specific risk mitigation strategies will underpin clinical roll- out of this clinical 
study. 
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  28 of 97 
 
CONFIDENTIAL  7 STUDY OBJECTIVES  
7.1 Primary Objective  
The primary objective of the study is: 
• To compare the efficacy of 6.0, 7.5, and 9.0 g of FT218 to placebo in treating EDS in 
both NT1 and NT2 subject s as measured by mean sleep latency on the Maintenance of 
Wakefulness  Test (MWT) and by the Clinical  Global Impression (CGI) rating of 
sleepiness  
• To compare the efficacy of 6.0, 7.5, and 9.0 g of FT218 to placebo in treating cataplexy 
in NT1 subjects as measured by the number of cataplexy attacks (NCA) determined from the cataplexy frequency item in the Sleep and Symptom Daily Diary 
7.2 Secondary /Exploratory Objectives 
The secondary /exploratory objectives of the study are to compare the efficacy of 6.0, 7.5, and 9.0 
g of FT218 to placebo for the following outcomes: 
7.3 Safety Objective  
The safety objective of the study is: 
• To evaluate the relative safety of FT218 compared to placebo. 

Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  29 of 97 
 
CONFIDENTIAL  8 INVESTIGATIONAL PLAN 
8.1 Overall Study Design and Plan: Description  
This is a Phase 3 double-blind, randomized, placebo-controlled, 2- arm clinical study. The 
purpose of this study is to assess the efficacy and safety of a once nightly formulation of sodium 
oxybate for the treatment of EDS and cataplexy in subject s with narcolepsy. Two populations of 
narcoleptic subjects will be studied in a single parallel group design: 1) NT1, and 2) NT2. 
The study treatment period from screening to follow- up will last approximately 17 weeks. There 
is a 3 -week screening p eriod, followed by a cen tral assessment of PSG and next-day MW T 
screening results  (may take up to 3 days). If the subject is eligible, then randomization occurs. 
After randomization, dosing must start within 5 days ( the window from randomization to dosing 
is to allow delivery of study drug to the site). There is a 13-week treatment period and a 1- week 
follow-up period. For subject s randomized to the active arm of the study the maximum duration 
of treatment with FT218 will be 13 weeks incorporating up- titration over a period of 8 weeks 
with 5 weeks on stable dosing at 9.0 g/night. For subject s randomized to placebo, there is no 
exposure to the study treatment.  
The follow-up study visit will occur at least 1 week after the last dose of FT218 or placebo i.e. 
Period 4 ( Visit 9, Week 1 5, Day 1 [ +4/-0 i.e.  a minimum of 7 days after the last on study dose] ). 
Additional follow- up for safety surveillance and management wil l be done for unresolved 
AE/residual effects of FT218 study drug following last dose as determined by the study 
investigator and/or sponsor.  
 

Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  30 of 97 
 
CONFIDENTIAL  8.1.1 Study Design  
Screening and Baseline  Rand Dose Titration  Dose Titration  Stable Dosing  EOS  FU 
            9.0g 9.0g 9.0g 9.0g 9.0g   
       7.5g 7.5g 7.5g 7.5g 7.5g        
     6g 6g             
   Arm 
1 4.5g               
                   
   Arm 
2 Placeb
o               
     Placeb
o Placeb
o             
       Placeb
o Placeb
o Placeb
o Placeb
o Placeb
o        
            Placeb
o Placeb
o Placeb
o Placeb
o Placeb
o   
                   
Visit 1   Visit 2 *  Visit 
3**  Visit 4 *   Visit 5   Visit 6 *   Visit 7    Visit 8 * Visit 9  
W-3 
D1  W-1 D7 
W0 D1  EOSc  
+2 D W1 D1  W3 D7 W4 D1  W6 D1  W8 D7 W9 D1  W11 
D1   W13 D7 W14 
D1 W15 
D1 
<------3 -week washout ----->                  
                   
W-3  W0  W1 W2 W3 W4 W5 W6 W7 W8 W9 W10 W11 W12 W13 W14 W15 
Period 1  Period 
2  Period 3a Period 3b(i)  Period 3b (ii) Period 3c(i)  Period 3c(ii)  Period 3c(iii)  Period 
4 
Abbreviations: D = day, EOS = End o f Study, EO Sc = End of Screening , FU = Follow -up, Rand = randomization, W = week, W/O = Washout  
*Study visits where baseline assessment or full efficacy assessment are  done extend into the following day and are thus indicated 
**Up to 6 days is allowed betwe en randomization (which occurs up to 2  days after the end of the screening  period) and dosing to allow shipment of study drug to site.  (Duration between  end of 
screening period and dosing is no more than 7 days.)  
 
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  31 of 97 
 
CONFIDENTIAL  

Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  32 of 97 
 
CONFIDENTIAL  

Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  33 of 97 
 
CONFIDENTIAL  

Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  34 of 97 
 
CONFIDENTIAL  

Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  35 of 97 
 
CONFIDENTIAL  8.2 Discussion of Study Design  
The rationale for the study design can be found in Section  6.  
8.3 Selection of Study Population 
8.3.1 Number of P lanned S ubjects  
8.3.2 Inclusion Criteria  
To be eligible for study entry subjects must sati sfy all of the following criteria  at the screening 
assessment visit : 
1. Male or female subject s 16 years of age or older 
2. Willing and able to give written informed consent for study participation. For young 
adults (16 and 17 years old) who have not reached the age of majority they must be capable of givi ng assent and consent from a legally authorized guardian must be 
obtained, as required by local laws and regulations 
3. Documented evidence of a diagnosis of NT1  or NT2  as, in part, determined by an 
overnight PSG and next- day MSLT with 2 or more SOREM Ps with mean sleep latency in 
the pathological range i.e. < 8 min utes and meeting the NT1 and the NT2 as defined by 
the International Classification of Sleep Disorders - 3 criteria
11 
4. Current continuing presence of EDS as defined by subject  report for the last 3  months 
and an ESS > 10 
5. For NT1 only, current continuing presence of cataplexy as defined by su bject  report for 
the last 3 months 
6. Subject s may use concomitant stimulants, but must comply with the following: 
a. They must be on a stable dose of stimulants for at least 3 weeks prior to starting the screening process for this study; AND 
b. They must use the same stimulant regimen throughout the entire study period, including during screening and posttreatment periods 
c. They  must discontinue all anti cataplexy drugs 
7. Female subjects who: 
a. Are postmenopausal for at least 1 year before t he screening visit 
b. Are surgically sterile, OR  

Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  36 of 97 
 
CONFIDENTIAL  c. If of child bearing potential agree to practice effective  double barrier  methods of 
contraception, from the time of the signing of informed consent through the last 
dose of study drug, or agree to completely abstain from heterosexual intercourse  
8. Willing and able to comply with all study mandated requirements and procedures for the duration of the clinical study  
9. Willing to adhere to all study restrictions including:   
a. Willingness to comply with the requirement to remain in bed for a minimum of 6 hours after taking the study drug 
b. Adherence to concomitant drug washout requirements, as applicable, for the duration of the clinical study. Refer to  Section 8.4.8.1 for a list  of all prohibited 
medications  
c. Willing to refrain from operating a car or heavy machinery if determined necessary by the investigator or willingness to refrain from operating a car or heavy machinery for at least 6  hours after taking the nightly dose of FT218  
d. Willing to abstain from alcohol for the duration of the clinical study 
e. If a smoker, willing to abstain from smoking at night from approximately 9 pm to  
7 am for the duration of the clinical study 
10. Evidence of adequate support for the duration of the study, including transportation to and from the study site if needed  
To be eligible for randomization , subjects must satisfy all of  the following criteria:  
1. Written informed consent obtained during the screening assessment visit  
2. Still eligible as per requirements in S ection 8.3.2 
3. Compliance with drug washout requirements  
4. Compliance in completing the study screening /baseline Sleep and Symptom Daily Diary. 
Compliance is defined as completing the diary at least 4 time s in each of the screening 
weeks  
5. Confirmation of EDS as defined by all of the following  
a. Baselin e ESS score > 10 points; AND  
b. Baseline MWT m ean sleep latency < 11 minutes following baseline PSG and as 
confirmed by the central scoring laboratory (Section  11.12)  
6. For NT1 only, current continuing presence of cataplexy as defined by an average of 8 reported cataplexy attacks per week in the screening /baseline S leep and Symptom Daily 
Diary 
7. Women of chil dbearing potential must have a negative serum pregnancy test at  screening 
and a negative urine test within 7 days prior to treatment  
 
8.3.3 Exclusion C riteria  
Subjects will be excluded from the study if one or more of the following criteria  are applicable:   
1. Prior use of sodium oxybate  is allowed in the study but with the following exclusions : 
a. Previous dosing must have be en limited to no more than 4.5g per night  
b. Patient should not have taken sodium oxybate for more than 2 weeks  
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  37 of 97 
 
CONFIDENTIAL  c. All previous dosing must not have occurred within the last year prior to entry to 
the study  
2. Current use of sodium valproate  
3. Any use of the following  prohibited medications for the duration of the clinical study: 
(Section 8.4.8.1)  
a. Anticonvulsants  
b. Clonidine  
c. SSRIs and serotonin and norepinephrine re-uptake inhibitors ( SNRIs ) 
d. MAOIs  
e. TCAs  
f. Hypnotics  
g. Anxiolytics  
h. Sedating antihistamines  
i. Antipsychotics  
j. Other experimental medications designed to treat narcolepsy, cataplexy or any other condition 
4. Treatment with any investigational products within 3 months  before study enrollment  
5. Any drug known to affect sleep- wake function. Concomitant stimulant use is permitted 
(Section 8.4.8)  
6. A diagnosis of sleep a pnea or any other sleep disorder known to cause EDS as 
determined by PSG and sleep history, including any PSG results indicating an apnea -
hypopnea index ( AHI) ≥ 15 
7. The presence of any unstable or clinically significant medical and psychiatric disorders (as determined by medical or psychiatric history, physical examination, and/or clinical 
laboratory test) which in the opinion of the investigator may either put the subject at risk by participation in the study, or may influence the results of the study 
8. Subje cts with a previous history or current ideation of suicide attempt  
9. Subjects who have a history of drug or alcohol use that, in the opinion of the investigator would interfere with study subject safety and adherence to study requirements  
10. Required commercial or equivalent driving during the study period 
11. An occupation that requires variable shift work or routine night shifts  
12. Any travel across more than 3 time zones during the course of the study  
13. Consuming more than 14 standard alcoholic drinks per week, on average, before  
participating in the clinical research study  
14.  Smoking during the night (approximately between 9 pm and 7 a m) during the course of 
the study 
15. Female subject s who a re lactating or h ave a positive  pregnancy test. Females of 
reproductive potential not willing or able to employ effective methods  of birth 
control/contraception to prevent pregnancy for the durati on of the study and for up to 1 
week after completing study treatment  
16. Any cur rent malignancy and/or any history of malignancy within last 3 years  
17. A history of seizure disorder, head trauma , or past invasive intracranial surgery  
18. Subjects with severe chronic obstructive pulmonary disease . Subjects with mild to 
moderate chronic obstructive pulmonary disease  and assessed as stable by the principal 
investigator ( PI) are eligible 
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  38 of 97 
 
CONFIDENTIAL  19. Principal investigator  judgement on other underlying respiratory and/or other underlying 
condition or disorder that would potentiate risk of respiratory or CNS depression with 
concomitant use of sodium oxybate  
20. Known hepatitis B surface antigen- positive status or known or suspected active hepatitis 
C infection  
21. Known human i mmunodeficiency virus infection or a cquired i mmunodeficiency 
syndrome related illness  
22. Schedul ed for procedures requiring general anesthesia during the study 
23. Known contraindication/allergy/sensitivity/intolerance to the study drug, sodium oxybate, or the inactive ingre dients of FT218 or placebo  
24. Atrial fibrillation or an abnormal electrocardiogram ( ECG) demonstrating clinically 
significant dysrhythmia(s)  
25. Recent myocardial infarction or coronary revascularization (less than 3 months)  
26. Uncontrolled hypertension 
27. Known  succini c semi -aldehyde dehydrogenase deficiency  
28. Moderately or severely altered blood c hemistry as defined by any one of the following:  
a. A Cockcroft -Gault calculated creatin ine clearance < 60 mL/min; OR  
b. Liver function tests more than twice the upper limit of normal; OR  
c. Serum bilirubin more than 1.5 times the upper limit of normal 
8.3.4 Removal of S ubjects F rom T herapy or A ssessments 
In accordance with the Declaration of Helsinki, subjects may withdraw consent to continued participation in the study at any time without giving a reason. This right will be respected 
without affecting the routine treat ment or care of the subject. If the reason for withdrawal is 
volunteered by the study subject it will be recorded in the subject’s medical notes and in the electronic case report form ( eCRF ). The Principal Investigator ( PI) will ensure the protection of 
the study subject’s interests is  prioritized.  
Study subjects must discontinue study drug and be withdrawn from the study for any of the following reasons.  
• Withdrawal of consent by the subject  
• Withdrawal of assent and corroborated by parent(s)/legal guardian  
• Any medical condition that the PI or sponsor  determines may compromise the study 
subjects safety by continuing to receive  study drug 
• Pregnancy  
• An AE or SAE which requires discontinuation from study drug 
• Inability to remain under medical observation for the duration of the study  
• Clinical risk of eme rgent suicidal ideation  
• Noncompliance to:  
o Study schedule  
o Sleep and Symptom Daily Diary completion requirements  
o Major deviation from protocol mandated procedures  
o Concerns over subject study drug handling in terms of subject safety, abuse , 
and/or dependence potential as determined by the PI  
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  39 of 97 
 
CONFIDENTIAL  • Any other situation where, in the opinion of the investigator  or the sponsor , continuation of 
the study would not be in the interest of the subject  
• Lack of efficacy  
• Discontinuation of the study by the sponsor  
• Regulatory authority decision or change in Independent Ethics Committee 
(IEC)/Institutional Review Board ( IRB) opinion for drug safety problems  
Irrespective of reason for withdrawal or discontinuation the PI must record the reason for 
withdrawal (if subject initiated w ithdrawal, this information must be voluntarily given by the 
subject). All data available for the study subject at the time of withdrawal/discontinuation must be recorded in the eCRF, unless specified otherwise by the subject. The PI will request that the subject return  all study drug and may request a follow -up visit especially if any adverse event(s) 
remain unresolved.  
In the event a subject does not return for a scheduled visit after withdrawal, every effort should be made to contact the subject. This s hould be documented. Every effort to document subject 
outcome should be made.  
PSG and MWT are at the discretion of the PI and consent of the subject. Early withdrawal study 
subjects will be followed for a week after the last dose of study drug. All SAEs and nonserious 
AEs assessed by the PI as related to the study drug should be followed to resolution or until the PI assesses them to be chronic or stable.  
It will be left to the investigator ’s clinical judgement whether or not an AE is of nature, or 
severity to require the subject’s removal from treatment. A subject may also voluntarily 
withdraw from treatment due to what is perceived as an intolerable AE. If either of these occurs, 
the subjects must undergo an end- of-study assessment and receive appro priate care under 
medical supervision until symptoms cease or the condition becomes stable.  
Withdrawal due to an AE should be distinguished from withdrawal due to lack of efficacy.  
If the subject withdraws due to a SAE, the SAE must be reported in accorda nce with SAE 
reporting requirements.  
Randomized subjects who have received at least 1  dose of study drug, who withdraw from the 
study prematurely will not be replaced.  
8.3.4.1 Pregnancy  
Study subjects may not be pregnant or nursing during the course of this study as indicated in the inclusion and e xclusion c riteria. Subject s of childbearing potential include all females who are 
not postmenopausal for at least 1 year before the screening visit and are not surgically sterile.  
All female subject s of childbearing potential must agree to practice 2 effective methods of 
contraception, from the time of the signing of informed consent through the last dose of study drug or agree to completely abs tain from heterosexual intercourse.  
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  40 of 97 
 
CONFIDENTIAL  For all women of childbearing potential a serum pregnancy test will be performed at screening 
and a urine pregnancy test will be performed at least 7 days before commencing FT218/placebo 
dosing. The results must be avai lable, documented and negative before the first dose of study 
drug is administered.  
After study drug is dispensed at Visit 3, urine pregnancy tests will be repeated at each study visit 
throughout the remainder of the study, including the final study visit  (Visit 9) or at the 
withdrawal visit if the subject  withdraws from the study. 
The investigator must report to the sponsor  any pregnancy occurring in a study subject, during 
the subject’s participation in this study.  The study Pregnancy Reporting F orm will be used. The 
report will be submitted within the same timelines as an SAE.  
For a study subject, the outcome of the pregnancy should be followed up carefully, and any 
abnormal outcome of the mother or the child should be reported. In some circumstances, it may 
be necessary to monitor the development of the newborn for an appropriate period after delivery.  
Although pregnancy is not an SAE, and an elective abortion is not an SAE, any spontaneous 
abortion and/or any pregnancy that mee ts any regulatory serious criterion, or any pregnancy with 
an outcome for the pregnant person or the infant that meets regulatory serious criterion will be captured as an SAE.  
8.4 Investigational Product  
The active ingredient of FT218, sodium oxybate ( GHB ), is a CNS depressant. Drug product 
formulations containing GHB that have no m arketing a uthorization are classified as Schedule I 
controlled substances  within the US. For all non- US sites classification across regions can vary, 
local/regional classification will apply.  
This study has been developed to ensure all local legal and regulatory requirements for the safe 
handling of Schedule I/Controlled Drug for all participating regions in the CLFT218- 1501 
clinical study are adhered to. 
8.4.1 Investigational Products Adm inistered  
8.4.1.1 Definition of a Schedule I /Controlled Drug  Substance  
A substance where there is no current accepted medical use in treatment, a lack of accepted 
safety for therapeutic use under medical supervision and a high potential for abuse.  
8.4.1.2 FT218 Study Drug Risk Management   
The CL FT218- 1501 operational framework will be structured to mitigate safety, abuse, misuse, 
and diversion risks associated with FT218. The framework will:  
1. Safeguard subject safety and mitigate abuse, misuse, and diversion risk s, and minimize 
potential for public -health risk through the implementation of best practice handling and 
distribution processes and procedures  
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  41 of 97 
 
CONFIDENTIAL  2. Allow for robust evaluation of emerging safety data and FT218 study drug management 
for detection of risk in terms of subj ect safety , abuse, and misuse  potential  
8.4.1.3 Specification for Managing Controlled Substances  
Systems and structures will be put in place to ensure compliance in the handling, distribution, 
prescription, and management of FT218. This will include :  
1. A “closed system” of FT218 distribution  
2. All study investigator s and investigative site facilities will be assessed and qualified in 
advance of site set up. Only investigative sites meeting requirements will be qualified for participation in this clinical study. All qualified investigative sites will be monitored on an ongoing basis for the duration of the clinical study to ensure ongoing compliance with 
all legal and regulatory requirements as applicable to the FT218- 1501 clinical study 
3. Subject education on FT218 handling 
4. Key investigator requirements include but are not limited to:  
a. Authorization to prescribe the FT218 controlled substance by the jurisdiction in which they are licensed to practice  
b. Evidence of current registration (D rug E nforcement A gency  in the US, as per 
local/r egional requirements for non- US sites) for the handling of the FT218 
controlled substance  
c. Compl ying with all FT218 -1501 clinical study requirements and all legal and 
regulatory requirements specific to the safe handling and management of the FT218 drug product  
d. Awareness of ramifications of no ncompliance with requirements  
All site specific approvals, registration forms and/or exemptions (if applicable for the latter) will be filed in the local study file at each site and a copy from each site will be provided for filing in the Trial Master File.  
8.4.1.4 Drug Accountability  
Sites must have the appropriate registration and authorizations to manage Schedule  I/Controlled 
Drug s according to regional legal and regulatory requirements. Documented evidence of this 
authorization will be provided to the sponsor /designated contract research organization ( CRO ) 
before study site initiation.  
Optimized study drug supply strategy is being applied to safeguard against loss, diversion, or theft of product.  
All clinical drug supplies shipped to study sites  will have clear instruction on- site requirements 
for receipt of drug, inspection of the shipment, confirmation or receipt, and storage requirements , 
all of which will be compliant with all applicable regional/local legal and regulatory requirements .  
The FT218 pharmacy m anual will be issued to each study site and will include detailed 
instruction as to applicable country and state level requirements including: inventory, storage, randomization, dispensing, dosing requirements , and returns processes to final disposition.  
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  42 of 97 
 
CONFIDENTIAL  On receipt, clinical study material will be  transferred to a secure location  (appropriate for 
Schedule I /Controlled Drug ). The PI/designee will inspect the shipment and enclosed 
temperature monitoring device to verify that clinical study materials were received in an 
acceptable condition and that the specified quantities have reached the study site. The PI/designee will complete and return all necessary paperwork as specified in the p harmacy 
manual.  
Any quality issue, i .e. deficient clinical study material condition, appearance, documentation, 
labelling etc. either on shipment receipt or at any stage during t he study must be reported. 
Necessary corrective actions will be identified and implemented as determined by the 
CRO/ sponsor .  
Upon receipt of FT218 study drug at site the PI/designee will check and document:  
• Consistency of the FT218 study drug received against the shipping records  
• Integrity of packages and seals  
• Temperature records and temperature recording devices  
• Receipt of associated documents as detailed in the study pharmacy manual  
The PI/designee will file all related documentation and receipts to enable the tracking of product batches, shipping conditions a nd accountability in the study pharmacy file.   
FT218 study drug must be stored as per protocol requirements and as per applicable legal, regulatory and labelling requirements. Details of storage requirements will be specified in the study pharmacy manual. Access to where study drug is s tored must  be restricted to preapproved 
personnel.  
The location of the FT218 study drug will be recorded. FT218 study drug should not be moved from one storage location to another without prior approval from the CRO/ sponsor . Full 
traceability of study drug storage must at all times be in place.  
8.4.1.5 FT218/Placebo  
FT218 study drug and placebo for each dosing period will be provided in a kit. Study drug will be provided as a powder in a sachet which will be of child proof quality. Each kit will contain the requisite number of study drug dose sachets. S achet dose s of 3.0 g and 4.5 g will be provided. 
Subjects will reconstitute to achieve the target dose levels, as necessary .   
Treatment Arm 1  
The treatment with FT218 is started with a gradual up -titration to stab le dosing according to the 
following steps:  
 Starting Dose  
× 1 week  Titration Dose  
× 2 weeks  Titration Dose  
× 5 weeks  Stable Dosing Period  
× 5 weeks  
Arm 1  FT218 4.5 g  
(1 × 4.5 g sachet)  FT218 6.0 g  
(2 × 3 g sachets)  FT218 7.5 g  
(1 × 3 g sachet , 
1 × 4.5 g sachet)  FT218 9.0g  
(2 × 4.5 g sachet)  
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  43 of 97 
 
CONFIDENTIAL  Treatment Arm 2  
The treatment with placebo is started with a sham gradual up -titration to sham stable dosing 
according to the following steps:  
 Starting Dose  
× 1 week  Titration Dose  
× 2 weeks  Titration Dose  
× 5 weeks  Stable Dosing Period  
× 5 weeks  
Arm 2  Placebo  
(1 × 4.5 g match 
sachet)  Placebo  
(2 × 3 g match 
sachets)  Placebo  
(1 × 3 g, 1 × 4.5 g 
match sachet)  Placebo  
(2 × 4.5 g match sachet)  
 
8.4.2 Identity of Investigational Products  
Test medication: FT218: Sodium Oxybate for Extended- Release Oral Suspension  
Active substance      Sodium Oxybate  
Strength 3.0 and 4.5 g sachets (for dosing at 4.5, 6.0, 7.5, and 9.0 
g)  
Dosage form      Powder for oral suspension 
Manufacturer      Recipharm  
Batch release  :    FLAMEL TECHNOLOGIES  
Storage       Room t emperature  
Test Medication: Placebo  
Substance       Inert constituents  
Strength and Dose  Placebo;  packaging and labelling will indicate  doses as 
used in the active arm as per drug dosing schedule.  
Dosage form      Powder for oral suspension 
Manufacturer      Recipharm  
Batch release      FLAMEL TECHNOLOGIES  
Storage       Room t emperature  
8.4.3 Packaging and Label ling 
Study drug management , handling, packa ging, and labe lling will comply with all applicable 
regional/local legal, regulatory, GxP regulations and sponsor  requirements.  
Active Drug: Arm 1:  
A study kit will be provided to study subjects with enough study drug supply for the assigned dosing weeks . Active drug dose will be supplied in sachets. Tw o strengths will be supplied; 3.0 
and 4.5 g, with the exception of the Week 1 dosing kit which will only contain a single dose strength of 4.5 g. Study subjects will be instructed on reconstitution methods according to their drug dosing regimen as predetermined by the drug randomization schedule. Each allocated drug kit will supply study subjects with enough drug until their next scheduled st udy visit for 
assessment and resupply. No over supply will be provided.  
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  44 of 97 
 
CONFIDENTIAL  Placebo Match: Arm 2:  
Placebo kits and sachets will be identical in presentation and content feel to that of active drug. It 
will be labelled using the same strength dosages i.e.  3.0 and 4.5 g doses, with the exception of 
the Week 1 dosing kit, which will only contain a single dose strength of 4.5 g. Study subjects will be instructed on the reconstitution method identical to that of active study drug. Each allocated drug kit will supply study subjects with enough drug until their next scheduled study visit for assessment and resupply. No oversupply will be provided.  
Specifications of Study Drug Q uantities Supplied per K it per Dosing Week.  
Each study kit will provide enough study drug supply for the assigned dosing weeks. For weeks that require o vernight PSG and next-day MWT, as part of the full efficacy assessment 
requirement, study kit supplies will be modified to allow for study sites to dispense a single night time dose to subjects at the PSG laboratory. Kit supplies for such weeks will contain enough study drug for 6 nights of dosing in the home setting. Study drug dose for night 7 will be dispensed at the PSG laboratory.  
For all other weeks where there is no overnight PSG requirement study subjects will be supplied 
with the full quota of 7 nights drug supply for home dosing.  
Details of the specifications of study drug supply quantities for each week of dosing are 
presented in Appendix 17.2. 
Label ling 
FT218 and placebo will be dispensed to study subjects in a kit (s) containing study drug with 
sufficient drug supply to the next scheduled visit as detailed in Appendix 17.2.  
Label ling of both outer kit packaging and individual dosing sachets  for both FT218 and placebo 
will meet with all legal and regulatory labelling requirements . 
8.4.4 Method of  Assigning S ubjects to T reatment G roups  
The drug dispensing strategy will, where feasible, minimize quantities of study drug stored at site 
at any one time. This will be mediated thought a study specific interactive response technology (IRT)  system  (endpoint, San Francisco, US). 
Once the overnight PSG and next- day MWT has been completed, the results will be reviewed 
and scored by a central scoring laboratory ( Section 11.12). The targeted turnaround time for 
results following completion of MWT is ≤  2 days. Results will be transmitted to the study PI.  
Where possible , on the same day confirmation of subject PSG and MWT eligibility has been 
received from the central scoring laboratory and all other study entry criteria are met, the PI/designee will randomize the study subject.   

Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  45 of 97 
 
CONFIDENTIAL  All screening and baseline assessments confirming eligibility must be documented in advance of 
subject randomization to the double -blind study period. The PI/designee enters the information 
into the IRT system, and the appropriate study drug is sent to the site. This process may take up to 6 days. 
The study site will notify all subjects of their eligibility status. Where a subject is eligible, the 
site will clarify requirements and arrange the first dispensing visit with the subject i.e., Visit 3.  
1. Within 5 days of randomization where it took 2 days for the Central Scoring Laboratory 
to respond with the PSG/MWT eligibility response  
2. Within 6 days of randomization where it took 1 day for the Central Scoring Laboratory to respond with the PSG/MWT eligibility response  
As no oversupply of study drug will be provided. Study subjects will be reminded to adhere to 
the dosing schedule and assigned schedule of visits to the hospital/clinic. Periodically, electronic 
alerts via the ePRO systems will be sent to study subjects to promote compliance with the visit schedule and all dr ug handling and management requirements. 
Following randomization , study subjects will be treated with their assigned study drug for a total 
of 13 weeks or until unacceptable AEs , withdrawal of consent or other treatment discontinuation 
criteria are met.  
8.4.5 Selection of D oses in the S tudy  
A description of the selection of doses for the study is provided in Section 6.5. 
8.4.6 Selection and T iming of D ose for E ach S ubject  
Subjects will be instructed on the safe management of study drug within their residential setting.  
All FT218 study drug must be kept out of reach from children and stored safely and securely to 
protect it from theft. It must be stored at 25 °C with allowable excursions to 15° C to 30° C. 
As food significantly reduces the bioavailability of sodium oxybate , study subjects will be 
instructed to take their nightly dose at least 2 hours after eating.  
Study subjects will be instructed by study site staff on their nightly dosing regimen. 
Guidance for Unused or Missed Doses 
All doses of the study drug are intended to be taken as outlined in the protocol schedule. No 
doses should be missed or delayed due to subject  visit scheduling and/or drug dispensing 
activities . 
Reconstituted product should be taken on the night it is reconstituted. In the event that reconstituted drug is not used it must be stored securely and returned to the study site at the next visit. Any reconstituted but unused study drug should not be substituted for the following nights dosing.  
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  46 of 97 
 
CONFIDENTIAL  Any missed nightly doses of the study drug are not to be taken, and the study drug for that night 
returned to the study site staff at the next study visit. 
If there is a delay in taking the study drug or if the subject  inadvertently fall s asleep but wakes 
again prior to taking their study drug, a delayed start may be possible  provided both  the 
following criteria are met: 
1. Study subjects feel awake enough to prepare and take the study drug as directed; and  
2. Study subjects have a minimum of 6 hours  left to sleep prior to waking up in the 
morning  
In the event that fewer than 6 hours of possible sleep remain, subjects will be instructed to forego 
taking the study drug that evening. Subjects will b e advised on reporting requirements for any 
deviation to the protocol mandated dosing regimen. 
Study drug must be taken every night for the first week of s tudy drug administration (Week 1 ) so 
that subject s are adequately prepared for the first up -titration  at the end of that week. Thereafter, 
a maximum of 2  missed doses during each study period will be allowed. If, at any time, study 
subjects are not compliant with the study protocol dosing requirements , they may be withdrawn 
from further participation in the study. 
Should study subject s become ill during the study, they should contact the study coordinator to 
discuss the decision surrounding taking the study drug.  If study subjects are too ill to take study drug on the night of PSG , the PSG will be schedul ed for 
the following night. If this is not possible, or the subject remains ill the PSG for that period will 
not be done. In the event of a persistent AE and or where the study subject misses more than 2 
doses of study drug in a single dosing period the su bject will be assessed for potential withdrawal 
in conjunction with the sponsor.  
8.4.7 Study Blinding  and Unblinding Procedures  
Provisions to ensure the integrity of the study blind include:  
1. Provisioned drug product and placebo being identical in color, texture, taste , and 
appearance  
2. All packaging being identical between groups (other than study randomization number 
allocation and kit number)  
3. Label ling of FT218 study drug will preserve the double -blind integrity for the study 
4. No biological tests being completed during the study risk inadvertent unblinding to study treatment allocation  
To maintain the overall quality and integrity of CL FT218- 1501 clinical study data, a code break 
will only occur  in exceptional circumstances. Knowledge of the study subject’s drug assignment 
would occur in circumstances where subject safety is at risk and knowledge of assignment is critical to the clinical management and safety of the subject.  
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  47 of 97 
 
CONFIDENTIAL  In circumstances whe re unblinding is deemed to be necessary, the PI must first speak with the 
medical monitor . In case of emergency, or if the PI cannot reach the medical monitor , the PI will 
use his/her best clinical judgement, however, must notify the medical monitor  as soo n as 
possible. The PI will use the IRT  system and/or the toll- free helpline for unblinding.  
After unblinding of an individual subject, e very effort must be made by the PI to maintain the 
blind as far as possible. The PI will not reveal the treatment alloc ation to the study subject nor 
any other personnel involved in the conduct of this study as far as possible. This includes other 
study site personnel, study monitors, the study CRO/ sponsor  or associated external parties 
involved in the running of the FT218 clinical study.  
The PI will document in the subject ’s source documents and eCRF that the blind was broken but 
will not disclose the subject ’s drug assignment.  
Where the study blind is broken for emergency, the subject will be withdrawn from the study. The early withdrawal visit will be completed and the End of Study ( EOS )/Withdrawal eCRF 
form will be completed. Reason for withdrawal will be detailed code break and reason for code break will be documented. 
8.4.8 Prior and C oncomitant Therapy  
All concomitant medications are to be taken as prescribed during the clinical study. All 
concomitant medications will be documented in both source documents and eCRF.  
All medications  (narcolepsy and non- narcolepsy), including washout medications, taken within 
30 days of Visit 1 will be recorded in both source documents and eCRF at the screening and 
baseline visits . There will be ongoing recording of concomitant medications taken during the 
study. Permitted concomitant medications are: 
a. Modafinil or armodafinil  
b. Methylphenidate  
c. Dextroamphetamine  
d. Methamphetamine  
e. Mixed salts amphetamines (Adderall, Vyvanse, etc.)  
f. Medications used to treat other diseases/conditions with mechanisms of action that do not 
influence sleep -wake function ( i.e., ins ulin for diabetes or levothyroxine for 
hypothyroidism ) 
8.4.8.1 Prohibited Medication/Therapy  
The following concomitant medications are prohibited during this study:  
a. Prior use of sodium oxybate s allowed in the study but with the following exclusions.  
• Previous dos ing must be limited to no more than 4.5g per night  
• Patient should not have taken sodium oxybate for more than 2 weeks.  
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  48 of 97 
 
CONFIDENTIAL  • All previous dosing must not have occurred within the last year prior to entry to 
the study 
b. Sodium valproate  
c. Anticonvulsants  
d. Clonidine  
e. SSRIs and  SNRIs  
f. MAOIs  
g. TCAs  
h. Hypnotics  
i. Anxiolytics  
j. Sedating antihistamines  
k. Other experimental medications designed to treat narcolepsy, cataplexy or any other condition 
l. Antipsychotics  
8.4.9 Treatment C ompliance  
Study subjects will receive training from study site staff who will have received protocol and study specific training from the CRO/ sponsor . Site training will occur in the study set up period 
(i.e. at the i nvestigator  meeting and/or at the site initiation visit) . Additional site training will be 
facilitated at study monitoring visits where appropriate via study manuals and guides.  
Site staff will have documented training on the study protocol and will be aware of all 
requirements and advisory to give to study subjects and where applicable family members .  
Site staff will be both capable and competent in clinical care management of subjects with 
narcolepsy and will be responsible for monitoring and advising subjects on the key safety  risks 
associated with the FT21 8 drug product.  
Study subjects will be informed on all requirements  for the safe handling and self -administration 
of study drug. They will be both familiar and comfortable with its presentation, handling, and reconstitution. All training provided to study subjects must be document ed.  
Subject training will include:  
1. Subject family members, where appropriate, will engage in the training process to allow for additional subject support in the home setting in both the drug reconstitution process and all of the  safety, procedural and visit scheduling requirements for this study. The 
parent (s)/legal guardian of study subjects who have not reached the age of majority will 
be included in the study training process  
2. Study subjects will be advised on the food requirem ent i.e.  dosing at least 2 hours  after 
the evening meal , and dietary salt restrictions , if applicable  
3. Study subjects will be advised on best practice for study drug storage relative to their specific living arrangements . Site staff must be satisfied that study subjects have the 
necessary comprehension of what is required for study drug storage (both pre and post 
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  49 of 97 
 
CONFIDENTIAL  reconstitution) and the necessary facilities, and contingency if away from their usual 
residence to store study drug safely 
4. Study subjects will be advised on the potential side effects of study drug and will receive instruction on what to do in the event of a health-related emergency. Additionally, they will be advised on how and when to report such events to the site  
5. Study subjects will be provided with emergency site contact numbers in the event of an emergency. To circumvent risk in the case of a health -related emergency all study 
subjects will be provided with an alert card with details of subject study participation with the FT218 sodium oxybate for extended-release oral suspension product. This card will flag that they are on a clinical study with a 1:1 chance that they are receiving a new extended -release oral suspension  formulation of sodium oxybate. The contact detail s of 
the PI will be provided 
6. Study subjects will be advised on rationale and importance of adhering to study restrictions  
7. Subjects will be advised of what to do in the event of suspected loss or theft of drug product 
8. Study subjects will be advised on study drug returns requirements. This will include detail on what to do with: 1) unused and unopened study drug, 2) what to do with reconstituted and unused study drug, 3) requirement for the return to site of al l empty 
study drug sachets 
9. Study subjects will be trained on using the ePRO device.  
The site staff will assess subjects to determine the need for additional training at each study visit.  
On return visit, the PI or designee will assess study subject compliance both verbally and by 
inventory of returns. All returns i.e. used, reconstituted and unused, and unopened study drug will be inventoried. Any deviation from dosing schedule will be documented and asse ssed for 
criteria for withdrawal.  
9 TIMING  OF STUDY PROCEDURES  
Study subjects will receive study drug (FT218 or placebo) as outpatients. The study is divided into 4 sequential periods with a total of 9 required study visits. One in Period 1, one in Period 2, six in Period 3 (the double-blind period) concluding with a single follow-up visit in Period 4.  
Where additional study visits are clinically required an unscheduled visit will be performed. A separate unscheduled eCRF visit module will be completed to record these visits. A set minimum of procedures to capture subject safety and progress will be done at the unscheduled visit, requirement s for additional procedures will be determined by the PI/designee.  
For early withdrawal, the EOS/Withdrawal eCRF module will be completed. In addition the EOS /Withdrawal eCRF page must be completed detailing the reason for subject withdrawal. The 
reason for withdrawal must also be recorded in the source documents.  
Subjects will provide written informed consent as appropriate and according to local laws and 
regulations, before any study- related procedures are per formed.  
 

Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  50 of 97 
 
CONFIDENTIAL  9.1 Pre-treatment  – Periods  1 and 2  
9.1.1 Period 1: Visit 1 (Week - 3, Day 1) Screening and Assessment  
Period 1 of the study commences with Visit 1. The purpose of this visit is to include subjects 
who meet the primary enrol lment criteria for the study. All information collected will be clearly 
documented i n the subject’s medical notes. The following assessments will be performed:  
• Complete informed consent procedures. Two originals of the subject  information 
leaflet/informed consent and assent form, where applicable, must be collected. One will be given to the subject, one will be filed in the study site file, and a copy will be made and filed in the subject's medical note  
• Record demographic data  
• Assess for s ubject eligibility  
• Collect full medical  and surgical history. All baseline conditions will b e recorded in the 
subject's medical notes  
• Written confirmation of narcolepsy diagnosis by type i .e. NT1/NT2. A copy of all 
diagnostic records for narcolepsy, including, overnight PSG and next -day MSLT must be 
filed, and accessible to study monitors in the subject's medical notes.  
In addition, from historical PSG it must be confirmed that the subj ect did not have an AHI 
of ≥ 15 
• Collect f ull psychiatric history  
• Assess subjects for any prior or current drug abuse and dependence (whi ch will exclude 
study subjects)  
• Collect  concomitant medications taken within 30 days of Visit 1. Specifically the following 
will be documented:  
o Confirmation that the subject s prior to sodium oxybate , if any, meets with the 
inclusion/exclusion criteria i.e. Prior use of sodium oxybate is allowed in the study but with the following exclusions:  
a) Previous dosing must have be en limited to no more than 4.5g per night  
b) Patient should not have taken sodium oxybate for more than 2 weeks  
c) All previous dosing must not have occurred within the last year prior to entry to the study  
o Confirmation that the subject has no current expos ure to sodium valproate  
o Details of use of protocol prohibited concomitant medications: a nticonvulsants, 
clonidine , SSRIs and SNRIs, MAOI s, TCAs, hypnotics, a nxiolytics, s edating 
antihistamines, and a ntipsyc hotics within the last 30  days  
o Confirmation that the subject has not been exposed to any experimental medications designed to treat narcolepsy, cataplexy or any ot her condition within 
the last 3 months  
• Obtain c onfirmation of subject's agreement to comply with the study washout requirements 
for prohibited medications for the duration of the clinical study 
• Record subject al cohol , caffeine,  and nicotine consumption (s tudy restriction questions)  
o Obtaining c onfirmation of subject ’s agreement to abstain from alcohol for the 
duration of the study 
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  51 of 97 
 
CONFIDENTIAL  o For smokers, obtain confirmation of subject's agreement to adhere to study 
mandated smoking restrictions for the  duration of the clinical study 
• Conduct screening C -SSRS (any current suicidal ideation or attempt will exclude subject)  
• Conduct obstructive sleep apnea assessment, including measurement of subject’s neck 
circumference and documentation of snoring patterns  
• Perform complete physical examination  
• Collect height (cm), weight (kg) and calculate body mass index (kg/m²)  
• Record v ital signs (systolic and diastolic BP , heart  rate)  
• Perform a 12- lead ECG  after subject has been supine  for 5 minutes  
• Collect samples for hematology, biochemistry, hepatitis B surface antigen ( HBsAg ) and 
anti-hepatitis C virus HCV antibody (HCVAb)  
• Collect  sample for serum pregnancy test (female subjects)  
• Collect  sample for uri nalysis, and urine drug screen (includes benzodiazepines, cannabis, 
cocaine, opiates, and barbiturates)  
• Administer ESS  
• Provide ePRO device , and  training and education on its use as it relates to study protocol 
diary records, drug adherence record and notifications and all other subject  facing 
applications  
• Expla in Slee p and Symptoms Daily  Diary completion. I nform subjects that for  ongoing 
eligibility they must complete the Sleep and Symptom Daily  Diary every day during P eriod  
1 (every day for the 3 -week period)  
• Provide  all necessary materials for participation including emergency site contact numbers  
advising subjects  that they can contact the site at any time should they have any concerns 
or questions  
• Schedule  Visit 2 with overnight PSG and next -day MWT with the subject  
• Update the IRT system with subject details and planned Visit 2 date  
This visit marks the beginning of the washout period when prohibited concomitant medications are no longer permitted.  
9.1.2 Period 2: Visit 2 (Week - 1, Day 7) Baseline Visit  
Following the screening visit, the second stage of subject assessment for continued eligibility will occur at the baseline  visit i.e.  Visit 2.  
At this visit the PI/designee  will firstly assess for:  
• Confirmation of continued eligibility  
• Compliance with drug washout requirements  
• Assess compliance with alcohol consumption, abstinence from alcohol , and all o ther study 
restrictions (study  restriction questions)  
• Assess drug abuse and dependence. Clinical judgement to be exercised in determining need for performi ng additional urine drug screen for benzodiazepines, cannabis, cocaine, opiates 
and barbiturates at this visit  
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  52 of 97 
 
CONFIDENTIAL  • Compliance in completing the screening/baseline Sleep a nd Symptom Daily D iary.  
Compliance is defined as completing the diary at least 4 times in  each of the screening 
weeks.  
o Confirmation of continued presence of cataplexy (NT1 subject s only) as defined 
by an average of 8 reported cataplexy attacks per week as reported in the Sleep 
and Symptom Daily Diary 
• EDS as defined by a  baseline  ESS score > 10 points  
If these criteria are met the following assessments and procedures will occur:  
• Review and record  all concomitant medication  
o Assess for adherence to prohibited medication requirements  
• Document any AEs  
• Complete baseline CGI  assessment of s everity of sleepiness (by investigator)  
• Administer baseline C -SSRS questionnaire  
• Perform complete physical exam  if determined clinically indicated by the PI  
• Record vital signs (systolic and diastolic BP , heart  rate)  
• Collect samples for hematology and biochemistry  
• Collect sample for urinalysis  
• Perform urine pregnancy test (female subjects)  
• Update the IRT system with planned Visit 3 date  
If all assessment s are satisfactory the study subject will then progress to having overnight 8- hour 
PSG wit h next -day 5 hour nap MWT. Results will be reported from the central scoring 
laboratory ( Section  11.12) .  
9.1.2.1 Central Scoring L aboratory: PSG and MWT  (+ 2  Days for results)  
Once the overnight PSG and next -day MWT has been completed, the results will be reviewed 
and scored by a central scoring laboratory  (Section  11.12) . The targeted turnaround time for 
results following completion of MWT is ≤  2 days. Results will be transmitted to the study PI.  
Once confirmation of subject PSG and MWT eligibility has been received from the central 
scoring laboratory and all other study entry criteria are met, the PI/ designee  can randomize the 
study subject.  
9.1.2.2 Randomization  
Where possible, on the same day confirmation of subject PSG and MWT eligibility has been 
received from the central scoring laboratory and all other study entry criteria are met, the PI/designee will randomize the study subject . There is no clinic visit for randomization, i.e. , 
the subje ct is not present at site.  
All screening and baseline assessments confirming eligibility must be documented in advance of subject randomization to the double -blind study period. The PI/designee enters the information 
into the IRT  system, and the appropriat e study drug is sent to the site. This process may take up 
to 6 days.  
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  53 of 97 
 
CONFIDENTIAL  Study treatment must begin:  
1. Within 5 days of randomization where it took 2 days for the Central Scoring Laboratory 
to respond with the PSG/MWT eligibility response  
2. Within 6 days of randomization where it took 1 day for the Central Scoring Laboratory to respond with the PSG/MWT eligi bility response  
The study site will notify all subjects of their eligibility status. Where a subject is eligible, the 
site will clarify requirements and arrange the first dispensing visit with the subject i.e., Visit 3.  
The CRO/ sponsor  must be notified of any deviations to this. Deviations are to be documented.  
9.2 Treatment Period – Period 3 (Dose Titration and Stabilization)  
9.2.1 Period 3a: Visit 3 (Week 1, Day 1) Dose Titration to 6.0 g/Night  
Period 3a  will commence at V isit 3 with provision of the study drug to the subject . This marks 
the start of the double -blind period.  
Dose titration steps for this period:  
• Week 1: 1st week on study drug in this period: 4.5 g/night of FT218 or placebo  
• Week 2 : 2nd week on study drug: Increase dose by 1.5 g/night for a dosing regimen of 
6g/night of FT218 or placebo  
• Week 3 : 3rd week on study drug: No dose increment -  dosing regimen remains at 
6.0 g/night of FT218 or p lacebo  
The following assessments and procedures will be performed at Visit 3 :  
• Compliance wi th drug washout requirements  
• Confirmation of continued eligibility  
• Assess study restrictions compliance: (i)  abstinence from alcohol, (ii) smoking restrictions, 
and (iii) all other study restrictions  
• Assess drug abuse and dependence. Clinical judgement to be exercised in determining need for performing urine drug screen for benzodiazepines, cannabis, cocaine, opiates, and barbiturates  
• Review and record all concomitant medication  
o Assess for adherence to prohibited medication requirements  
• Document any AEs  
• Administer “since last visit” C -SSRS questionnaire  
• Perform p hysical examination if determined clinically necessary by the PI  
• Perform urine pregnancy test (female subjects)  
• Record vital signs (systolic and diastolic BP  and heart rate)  
• Collect weight 
• Educati on & training and assessment of study subject on- study requirements and study 
drug reconstitution, compliance, management, prohibited medications, subject self -care 
and safety  
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  54 of 97 
 
CONFIDENTIAL  • Dispense study drug  
• Remind subject about instructions  on Sleep and Symptom Daily Diary  completion us ing 
the ePRO device  
If the PI is concerned that the study subject will be unable to comply with FT218 study drug and 
study requirements following the  training and education session the subject will be informed and 
withdrawn  from study.  
• Schedule Visit 4 with the study subject  
• Update IRT system with subje ct’s details for next visit  
9.2.2 Period 3b (i): Visit 4 (Week 3, Day 7) Dose Titration to 7.5 g /Night  
Dose titration steps for this period:  
• Week 4: 1st week on study drug in this period: Increase dose by 1.5 g/night for a dosing 
regimen of 7.5 g/night of FT218 or placebo  
• Week 5 : 2nd week on study drug: 7.5 g/night of FT218 or placebo.  
Visit 4  includes a full efficacy assessment  (evaluation of the 6.0 g efficacy) . Procedures at this 
visit include:  
• Compliance with drug washout requirements  
• Confirmation of continued eligibility  
• Assess study restrictions compliance: (i)  abstinence from alcohol, (ii) smoking restrictions, and (iii) all other study res trictions  
• Assess for drug abuse and dependence. Clinical judgement to be exercised in determining 
need for performing urine drug screen for benzodiazepines, cannabis, cocaine, opiates, and 
barbiturates  
• Assess compliance with drug handling, management , and safety requirements  
o Confirm subject is adhering to requirement to eat at least 2 hours before taking study drug 
o Subject re- education on study drug safety and handling and study- related 
procedures if deemed necessary by PI  
• Review and record of concomitant medication  
o Assess for adherence to prohibited medication requirements.  
• Document any AEs  
• Collect CGI  assessment of improvement in sleepiness ( investigator blinded to MWT 
results ) 
• Administer “since last visit” C -SSRS questionnaire  
• Perform physical examination  if determined clinically indicated by the PI  
• Record v ital s igns (systolic and diastolic BP  and heart rate)  
• Perform u rine pregnancy test  (female subjects)  
• Review and confirmation of ePRO diary and questionnaire completion (on subject questioning and ePRO check).  
o Self-record ed study drug compliance record (with returns check)  
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  55 of 97 
 
CONFIDENTIAL  o Compliance with Sleep and Symptom Daily Diary completion requirements for 
the past 3- week period. Completion of ESS (subject  questionnaire)  
• Overnight PSG  
o Next -day 5 hour  nap MWT  
• Dispense d rug and perform accountability  
• ePRO device handling and ePRO completion requirements and consequences of poor compliance will be discussed again with the study subject  
o Study subjects will be instructed to complete their Sleep and Sy mptom Daily 
Diary  on a daily basis for the next 2 weeks  
If the PI is concerned that the study subject will be unable to comply with FT218 study drug and study requirements following training and education session the subject will be informed and withdrawn from study.  
• Schedule Visit 5 with the study subject  
• Update IRT system with subject’s details for ne xt visit and study drug returns  
9.2.3 Period 3b (ii): Visit 5 (Week 6, Day 1) 7.5 g/Night  
There are no dose titration steps for this period:  
• Week 6 : 1st week on study drug:  7.5 g/night of FT218 or placebo  
• Week 7 : 2nd week on study drug: 7.5 g/night of FT218 or  placebo  
• Week 8 : 3rd week on study drug: 7.5 g/night of FT218 or placebo  
Visit 5 incl udes a partial efficacy assessment . Procedures at this visit include:  
• Compliance with drug washout requirements  
• Confirmation of continued eligibility  
• Assess study restrictions compliance: (i)  abstinence from alcohol, (ii) smoking restrictions, 
and (iii)  all other study restrictions  
• Assess drug abuse and dependence. Clinical judgement to be exercised in determining need for performing urine drug screen for benzodiazepines, cannabis, cocaine, opiates and barbiturates  
• Assess compliance with drug handling, m anagement , and safety requirements  
o Confirm subject is adhering to requirement to eat at least 2 hours before taking study drug 
o Subject re- education on study drug safety and handling and study- related  
procedures if deemed necessary by site PI  
• Review and record of concomitant medication  
o Assess for adherence to prohibited medication requirements  
• Document any AEs  
• Complete CGI assessment of improvement in sleepiness (investigator blinded to MWT results)  
• Administer “since last visit” C -SSRS questionnaire  
• Perform p hysical examination  if determined clinically indicated by the PI  
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  56 of 97 
 
CONFIDENTIAL  • Record v ital s igns (systolic and diastolic BP  and heart rate)  
• Perform u rine pregnancy test  (female subjects)  
• Review and confirmation of ePRO diary and questionnaire completion: (on subje ct 
questioning and ePRO check)  
o Self-record ed study drug compliance record (with returns check)  
o Compliance with Sleep and Symptom Daily Diary completion requirements for 
the past 2- week period. Completion of ESS ( subject  questionnaire)  
• Dispense drug and perform accountability  
• ePRO device handling and ePRO completion requirements and consequences of poor compliance will be discussed again with the study subject  
o Study subjects will be instructed to complete their Sleep and Sy mptom Daily 
Diary  on a daily basis for the next 3 weeks.  
If the PI is concerned that the study subject will be unable to comply with FT218 study drug and study requirements following training and education session the subject will be informed and withdraw n from study.  
• Schedule Visit 6 with the study subject  
• Update IRT system with subject’s details for ne xt visit and study drug returns  
9.2.4 Period 3c(i): Visit 6 (Week 8 , Day 7) Dose Titration to 9.0 g/Night, Stabilization  
Dose titration and stabilization steps for this period:  
• Week 9: 1st week on study drug in this period: Increase dose by 1.5 g/night for a dosing 
regimen of 9.0 g/night of FT218 or placebo  
• Week 1 0: 2nd week on study drug: 9.0 g/night of FT218 or placebo.  
This visit includes a full efficacy assessment (evaluation of the 7.5 g efficacy). Procedures at this 
visit include:  
• Compliance with drug washout requirements  
• Confirmation of continued eligibility  
• Assess study restrictions compliance: (i)  abstinence from alcohol, (ii) smoking restrictions, and (iii) all other study restrictions  
• Assess drug abuse and dependence. Clinical judgement to be exercised in determining need for performing urine drug screen for benzodiazepines, cannabis, cocaine, opiates and barbiturates  
• Assess compliance with drug handling, management and safety requirements  
o Confirm subject is adhering to requirement to eat at least 2 hours before taking study drug 
o Subject re- education on study drug safety and handling and study- related 
procedures if deemed necessary by site PI  
• Review and record of concomitant medication  
o Assess for adherence to prohibited medication requirements  
• Document AEs  
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  57 of 97 
 
CONFIDENTIAL  • Complete CGI assessment  of improvement in sleepiness ( investigator blinded to MWT 
results)  
• Administer “since last visit” C -SSRS questionnaire  
• Perform p hysical examination  if determined clinically indicated by the PI  
• Collect vital signs  (systolic and diastolic BP  and heart rate)  
• Perform u rine pregnancy test  (female subjects)  
• Review and confirmation  of ePRO diary and questionnaire completion: (on subje ct 
questioning and ePRO check)  
o Self-recorded study drug compliance record (with returns check)  
o Compliance with Sleep and Symptom Daily Diary completion requirements for 
the past 3- week period. Completion of ESS  (subject  questionnaire)  
• Overnight PSG  
o Next -day 5 hour nap MWT  
• Dispense  drug and perform accountability  
• ePRO device handling and ePRO completion requirements and consequences of poor compliance will be discussed again with the study subject  
o Study subjects will be instructed to complete their Sleep and Symptom Daily 
Diary  on a daily basis for the next 2 weeks  
If the PI is concerned that the study subject will be unable to comply with FT 218 study drug and 
study requirements following training and education session the subject will be informed and withdrawn from study.  
• Schedule V isit 7 with the study subject  
• Update IRT system with subject’s details for ne xt visit and study drug returns  
9.2.5 Period 3c (ii): Visit 7 (Week 11 , Day 1) Stabilization  
Stable dosing:  
• Week 1 1: 1st week on study drug in this period: 9.0 g/night of FT218 or placebo  
• Week 12 : 2nd week on study drug: 9.0 g/night of FT218 or placebo  
• Week 13 : 3rd week on study drug: 9.0 g/night  of FT218 or placebo  
Visit 7 includes a partial efficacy assessment. Procedures at this study visit include:  
• Compliance with drug washout requirements  
• Confirmation of continued eligibility  
• Assess study restrictions compliance: (i)  abstinence  from alcohol, (ii) smoking restrictions, 
and (iii) all other study restrictions  
• Assess drug abuse and dependence. Clinical judgement to be exercised in determining need 
for performing urine drug screen for benzodiazepines, cannabis, cocaine, opiates and barbiturates  
• Assess compliance with drug handling, management , and safety requirements  
o Confirm subject is adhering to requirement to eat at least 2 hours before taking study drug 
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  58 of 97 
 
CONFIDENTIAL  o Subject re- education on study drug safety and handling and study- related  
procedures if deemed necessary by site PI  
• Review and record of concomitant medication  
o Assess for adherence to prohibited medication requirements.  
• Document any AEs  
• Collect CGI  assessment of improvement in sleepiness  (investigator blinded to MWT 
results)  
• Administer “since last visit” C -SSRS questionnaire  
• Perform physical examination  if determined clinically indicated by the PI  
• Collect v ital signs (systolic and diastolic BP  and heart rate)  
• Perform u rine pregnancy test (female subjects)  
• Review and confirmation of ePRO diary and questionnaire completion: (on subject 
questioning and ePRO check)  
o Self-recorded study drug compliance record (with returns check)  
o Compliance with Sleep and Symptom Daily Diary completion requirement s for 
the past 2 -week period. Completion of ESS (subject questionnaire)  
• Dispense d rug and perform accountability  
• ePRO device handling and ePRO completion requirements and consequences of poor 
compliance will be discussed again with the study subject  
o Study subjects will be instructed to complete their Sleep and Symptom Daily 
Diary  on a daily basis for the next 3 weeks.  
If the PI is concerned that the study subject will be unable to comply with FT218 study drug and 
study requirements following training and education session the subject will be informed and withdrawn from study.  
• Schedule Visit 8 with the study subject  
• Update IRT system with subject’s details for next visit and study drug returns  
9.2.6 Period 3c(i ii) Visit 8 (Week 1 3, Day 7) End of Study (EOS)  
This visit include s a full efficacy assessment (evaluation of the 9.0 g efficacy).  
• Compliance with drug washout requirements  
• Confirmation of continued eligibility  
• Assess study restrictions compliance:  (i)  abstinence  from alcohol, (ii) smoking restrictions, 
and (iii) all other study restrictions  
• Assess drug abuse and dependence. Clinical judgement to be exercised in determining need 
for performing urine drug screen for benzodiazepines, cannabis, cocaine, opiates and 
barbiturates  
• Assess compliance with drug handling, management and safety requirements  
o Confirm subject is adhering to requirement to eat at least 2 hours before taking study drug 
• Review and record of concomitant medication  
o Assess for adherence to prohibited medication requirements  
• Document any AEs  
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  59 of 97 
 
CONFIDENTIAL  • Complete  CGI assessme nt of improvement in sleepiness  (investigator blinded to MWT 
results)  
• Administer “since last visit”  C-SSRS questionnaire  
• Perform full physical examination  
• Collect weight  
• Collect v ital s igns (systolic and diastolic BP  and heart rate)  
• Collect samples for hematology, biochemistry, and perform urine pregnancy test  (female 
subjects)  
• Collect sample for urinalysis  
• Perform 12- lead ECG after subject is s upine  for 5  minutes  
• Review and confirmation of ePRO diary and questionnaire completion: (on subje ct 
questioning and ePRO check)  
o Self-recorded study drug compliance record ( with returns check)  
o Compliance with Sleep and Symptom Daily Diary completion requirements for 
the past 3- week perio d. Completion of ESS ( subject  questionnaire)  
• Overnight PSG  
o Next -day 5 hour nap MWT  
• Perform d rug ac countability and reconciliation  
• Update IRT system with E OS details and fin al subject drug accountability 
• Obtain  ePRO device from subject  and place in on -site safe storage  
• Schedule fol low-up visit with study subject  
9.3 Follow -up Period – Period 4  
9.3.1 Period 4 : Visit 9 (Week 15, Day 1) Follow -up 
A safety follow -up visit will take place at Week 15  Day 1 (+4/ -0) when subjects have been off 
study drug for ≥  1 week. Study procedures include:  
• Review and record all concomitant medication  
• Safety assessment: To include assessment for residual effects of study drug and all AE 
review.  
o All AEs including residual effects of study drug to be reported as per study 
protocol requirements. The outcome of any AEs with a date of onset during the double -blind period should be re evaluated and any new AEs shoul d be recorded. 
All SAEs and nonserious AEs assessed by the PI as related to the study drug 
should be followed to resolution or until the PI assesses them to be chronic or stable  
o In the event that a study subject is unable to return to clinic for the follow -up visit, 
telephone contact with the study subject to assess for AEs and or residual effects 
of study drug and concomitant medications is expected.  
• Perform p hysical examination if determined clinically indicated by the PI  
• Collect weight  
• Collect v ital signs (systolic and diastolic BP  and heart rate) if clinically in dicated  
• Collect samples for hematology or biochemistr y if clinically indicated , and perform u rine 
pregnancy test  (female subjects)  
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  60 of 97 
 
CONFIDENTIAL  • Discuss off -study narcolepsy therapeutic pathway with study subject  
9.4 Unscheduled Visits  
Where additional study visits are clin ically required an unscheduled visit will be performed. 
Where an unscheduled visit leads to the subject ’s withdrawal, the procedures to be performed are 
those planned for the E OS visit as detailed in Section  9.2.6. 
Study procedures include:  
• Compliance with drug washout requirements  
• Confirmation of continued eligibility  
• Assess study restrictions compliance: (i)  abstinence  from alcohol, (ii) smoking restrictions, 
and (iii) all other study restrictions  
• Assess drug abuse and dependence. Clinical judgement to be exercised in determining need 
for performing urine drug screen for benzodiazepines, cannabis, cocaine, opiates and barbiturates  
• Assess compliance with drug handling, management and safety requirements. 
o Confirm subject is adhering to requirement to eat at least 2 hours before taking study drug 
o Subject re- education on study drug safety and handling and study- related  
proce dures if deemed necessary by site PI  
• Review and record of concomitant medication  
o Assess for adherence to prohibited medication requirements  
• Document any AEs  
• Collect CGI assessment of improvement (investigator blinded to MWT results as applicable)  
• Administe r “since last visit” C -SSRS questionnaire  
• Perform p hysical examination*  
• Collect weight* 
• Record vital signs (systolic and diastolic BP  and heart rate) * 
• Collect samples for hematology *, biochemistry*, and perform urine pregnancy test (female 
subjects)  
• Perfo rm 12 -lead ECG after subject is s upine  for 5 minutes* 
• Review and confirmation of ePRO diary and questionnaire completion: (on subject 
questioning and ePRO check)  
o Self-recorded study drug compliance record ( with returns check) as applicable  
o Compliance with Sleep and Symptom Daily Diary completion requirements for 
the past period. Completion of ESS  (subject questionnaire)  
• Overnight PSG* 
o Next -day 5 hour nap MWT * 
• Schedule next or follow -up visit with study subject if not withdrawing at this visit.  
* At the PI’s discretion  
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  61 of 97 
 
CONFIDENTIAL  9.5 Duration of T reatment  
The duration of treatment will be  approximately 17 weeks. There will be a 3- week screening 
period, a 13- week treatment period , and a 1 -week follow -up period. 
Following the end of the subject’s participation in the clinical study, no further study drug will 
be dispensed. The study PI will determine the most suitable medical care for the subject. 
10 EFFICACY AND SAFETY VARIABLES   
 
10.1 Efficacy and Safety M easurements A ssessed   
10.1.1.1 Maintenance of Wakefulness Test  
The MWT  is an evaluation used as a quantitative PSG measurement of daytime 
wakefulness/somnolence.24 It shows whether or not a subject is able to stay awake for a defined 
period of time (90-minutes between one nap ending and the next one starting, spaced at 2 -hour 
intervals throughout the day). Sleep latency is assessed by the amount of time it takes for 
subject s to fall asleep during the test. The MWT is an indicator of how well subjects may be able 
to function and remain alert during quiet times of inactivity.  
10.1.1.2 Clinical Global Impression of Sleepiness  
At Visit 2 , the CGI assessment of severity of sleepiness scale will be conducted . At subsequent 
assessments, t he CGI  is evaluated on a 7-point scale, centered at No Change, and ranging from 
Very Much Worse to Very Much Improved. Subjects are rated by the qualified and approved evaluators who based their assessments on the severity of sleepiness at baseline.  
10.1.1.3 Sleep and Symptoms Daily  Diary  

Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  62 of 97 
 
CONFIDENTIAL  10.1.1.5
 Epworth Sleepiness Scale  
The E SS is intended to evaluate the extent of sleepiness in everyday situations by asking the 
subject  a series of questions. In these questions, subject s are asked to rate their chances of dozing 
during each of 8 activities on a scale from 0  through 3 (0=never; 1=slight; 2=moderate; 3=high). 
Higher total scores indicate a greater tendency to sleepiness.  
10.1.2 Safety Assessments 
10.1.2.1 Adverse Events  
Adverse Event D efinition  
An AE is defined as any untoward medical occurrence in a clinical study subject administered a 
medicinal product which does not necessarily have a causal relationship with this treatment. Adverse events may include, but are not limited to the following: abnormal test findings, clinically significant signs a nd symptoms, hypersensitivity, any signs and/or symptoms from: 
drug overdose, drug administration/reconstitution error, any drug misuse, accidental exposure withdrawal, and or interactions, and exposure in utero.  
Symptoms and signs of clinical and functional deterioration as defined in study efficacy 
assessment criteria for subjects with NT1 and NT2 will be not be captured as AEs. These signs and symptoms will be captured in the context of efficacy assessments via the ePRO enabled Sleep and Symptom Daily D iary, CGI rating of sleepiness, and on overnight PSG and next- day 5 
hour nap MWT and will be reported as part of the efficacy analysis.  
They include:  
• Excessive daytime sleepiness  
• Number of cataplexy attacks 
• Disturbed nocturnal sleep 
• Nightly arousals  
• Sleep quality  
• Refreshing nature of sleep 
• Sleep paralysis  
All other signs and symptoms of clinical and functional deterioration as they relate to the 
underlying diagnosis of narcolepsy (NT1 and NT2), study drug, and concomitant medications , or 
other will be recorded as AEs. 

Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  63 of 97 
 
CONFIDENTIAL  It is the responsibility of the investigator to document all AEs that occur during the study. AEs 
should be reported on t he appropriate page of the e CRF.  
Assessment of S everity  
Each AE will be  assigned a category by the investigator as follows:  
Mild : An AE that is easily tolerated by the subject, causes minimal discomfort , 
and does not interfere with everyday activities  
Moderate : An AE that is sufficiently discomforting to interfere with norma l 
everyday activities; intervention may be needed  
Severe : An AE that prevents normal everyday activities; treatment or other 
intervention usually needed  
If there is a change in severity of an AE, it must be recorded as a separate event.  
Assessment of C ausality 
For each recorded AE or SAE, the investigator or designee must make an assessment of causality based on the following criteria to determine the rela tionship between the AE and study drug:  
 
Classification  Investigator’s 
Judgement  Definition  
Not Related:  
assigned when:  Not related  Where an AE or SAE is judged to be clearly and incontrovertibly due only to 
extraneous causes (e .g. disease, environment) and does not meet the criteria for 
study drug relationship listed under likely, possibly , or unlikely  
Unlikely  The AE or SAE is unlikely related to the study drug, when the AE or SAE (the 
first 2 criteria must be met):  
• Does not fol low a reasonable temporal sequence from administration 
of the study drug  
• May readily have been produced by the subject’s clinical state, 
environmental, or toxic factors, or other modes of therapy 
administered to the subject 
• Does not follow a known pattern of response to the study drug  
• Does not reappear or w orsen when the study drug is re administered  
Related:  
assigned in any 
other cases when:  Possibly  The AE or SAE is possibly related to the study drug, when the connection to 
the study drug appears unlikely but cannot be ruled out with certainty. This 
causal relationship is assigned when the AE or SAE (the first 2 criteria must be 
met):  
• Follows a reasonable temporal sequence from administration of the study drug  
• May have been produced by the subject’s clinical state, environmental, 
or toxic factors or other modes of therapy administered to the subject.  
• Follows a pattern of response to the suspected study drug.  
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  64 of 97 
 
CONFIDENTIAL   
Related:  
assigned in any 
other cases when:  Related  The AE or SAE is considered related to the study drug, when the connection to 
study drug can be made with a high degree of certainty. This causal relationship 
is assigned when the AE or SAE (the first 3 criteria must be met):  
• Follows a reasonable temporal sequence from administration of the 
study drug  
• Cannot be reasonably explained by the known characteristics of the subject’s clinical state, environmental, or toxic factors, or other modes 
of therapy administered to the subject  
• Disappears or decreases upon cessation or reduction in dose (note that 
there are important exceptions when an AE or SAE does not disappear 
upon discontinuation of the study drug, yet drug relatedness clearly 
exists [e.g. bone marrow depression or tardive dyskinesia ]) 
• Follows a known pattern of response to the suspect study drug  
• Reappears upon re challenge  
 
If the investigator determines that the causality is unknown, the PI must then assign a causality 
of “Possibly” for the purposes of reporting. The causality must be clearly documented in the subject’s medical notes and e CRF and report in accordance with the SAE reporting requirements 
if applicable.  
Action T aken  
The investigator will describe the action taken in the appropriate section of the e CRF, as follows:  
• None 
• Study drug stopped 
• Study drug temporarily interrupted  
• Concomitant medication  
• Other, specify.  
Adverse Event Outcome 
The investigator will assess the outcome of the AE or SAE as follows:  
• Fatal (the subject has died)  
• Resolved (the AE or SAE has ended)  
• Ongoing (the AE has not ended)*  
• Unknown (lost to follow -up after repeated unsuccessful attempts to contact the subject)  
* An AE outcome can only be categor ized as ongoing if the AE is: 
• Ongoing at the end of the reporting period: improved, stable or worsening  
• Ongoing: improved, stable , or worsening, and referred to the subject’s physician or a 
specialist.  
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  65 of 97 
 
CONFIDENTIAL  Follow -up of A dverse E vents  
All investigators should follow up subjects with AEs until the event is resolved or until, in the 
opinion of the investigator, the event is stabil ized or determined to be chronic . Details of AE 
resolution must be documented in the e CRF.  
Subje cts should be followed for 7  days after  receiving the last dose of study drug, and any AEs 
that occur during this time should be reported according to the procedures outlined above.  
Documentation and R eporting of A dverse E vents  
Attention will be paid to the occurrence of AE s at all stages of the clinical study s tarting from 
signing of the informed consent to the follow -up visit which takes place 1 week after study 
completion or 1 week after premature withdrawal. Baseline events (i .e. medical history events 
that are ongoing) captured at the first study visit will only be recorded as AEs if during the 
screening  and assessment period or double -blind period there is  deterioration.  
Information regarding all AEs, including SAEs, will be collected at each visit. All AE/SAEs that are encountered during the protocol specified AE/SAE reporting period will be followed to their 
resolutions, until the investigator assesses them as stable, or the subject  is lost to follow -up.  
Adverse events will be identified as treatment- emergent (TEAE) if the event occurs or increases 
in severity after the first dose of study drug is taken.  
Adverse events considered related to study drug at the E OS or Early Withdrawal Visit ( if 
applicable) will be followed until the subject  is stable or the AE is resolv ed or the subject  is lost 
to follow -up. 
Adverse event data will be obtained at all study visits scheduled or unscheduled. Reporting will 
be based on information provided spontaneously by the subject  and/or through questioning of the 
subject .  
To elicit AEs, questioning at each study vis it should begin with simple nonleading questions.  
For example:  
• How have you felt since your last visit?  
• Have you had any health problems since you were here last?  
Complete an d appropriate data on all AEs experience (observed, volunteered or elicited) during 
the reporting period will be reported on an ongoing basis in the Adverse Event Form pages of the 
eCRF.  
The following information regarding any AE s will be determined and documented by the 
investigator.  
• Subject number  
• The event  (diagnosis preferred)  
• The relationship of the AE to the study drug (causal relationship)  
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  66 of 97 
 
CONFIDENTIAL  • Study drug information 
• Seriousness (serious or not serious)  
As the quality and precision of acquired AE data are critical, investigators will use the AE 
definitions provided in the protocol and will observe the following guidelines when describing adverse ev ents in the Adverse Event Form pages of the e CRF .  
• Whenever possible recogni zed medical te rms will be used to describe AE s rather than 
colloquialisms (for exa mple, “influenza” rather than “f lu”) and abbreviations will be 
avoided  
• Adverse events occurring secondary to other AE s (e.g. sequela or complications) will be 
identified by the primary cause. A primary AE , if clearly identifiable, generally represents 
the most accurate clinical term to record in the eCRF. The investigator will provide his/her 
opinion of which is the primary AE  
10.1.2.1.1 Serious Adverse Events  
Serious A dverse E vent Definition  
An SAE is any untoward medical occurrence or effect that, at any dose,  
• Results in death  
• Is life -threatening (an AE is life -threatening if the subject was at immediate risk of death 
from the event as it occurred, i .e. it does not include a reaction that might have caused 
death if it had occurred in a more serious form)  
• Requires or prolongs inpati ent hospitalization . (Complications occurring during 
hospitalization  are AEs and are SAEs if they cause prolongation of the current 
hospitalization . Hospitalization  for elective treatment of a preexisting nonworsening 
condition is not, however, considered an AE . The details of such hospitalization s must be 
recorded on the medical history or physical examination page of the eCRF)  
• Results in persistent or sign ificant disability/incapacity . (An AE is incapacitating or 
disabling if it results in a substantial and/or permanent disruption of the subject’s ability to 
carry out normal life functions)  
• Resu lts in a congenital anomaly/birth defect  
In addition, medical and scientific judgement is required to decide if prompt notifi cation is 
required in situations other than those defined for SAEs above . This may include  any event that 
the investigator regards as serious that did not strictly meet the criteria above but may have jeopard ized the subject or required intervention to pre vent one of the outcomes listed above, or 
that would suggest any significant hazard, contraindication, side effect , or precaution that may be 
associated with the use of the investigational product . 
Reporting of S erious A dverse E vents 
If a SAE occurs, the CRO /sponsor  is to be notified within 24 hours of awareness of the event by 
the investigator. If the SAE is fatal or life -threatening, notification to the CRO/ sponsor  must be 
made immediately, irrespective of the extent of available AE information. This timeframe also 
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  67 of 97 
 
CONFIDENTIAL  applies to additional new information (follow -up) on previously forwarded SAE reports as well 
as to the initial and follow -up reporting of e xposure in utero cases.  
In the rare event that the investigator does not become aware of the occurrence of a SAE 
immediately (eg, if an outpatient study subject initially seeks treatment elsewhere) the investigator is to report the event within 24 hours after learning of it and document the time of 
his/her first awareness of the AE.  
For all SAE s, the investigator is obligated to pursue and provide information to the CRO/ sponsor  
in accordance with the timeframes for reporting specified above. In addition, an investigator may 
be requested by the CRO/ sponsor  to obtain specific additional follow -up information in an 
expedited fashion. This information may be more detailed than that captured on the SAE form. It will describe the SAE in enough detail to allow for a complete medical assessment of the case. Additional information concomitant medications and illnesses must be provided. In the case of a subject death, a summary of available autopsy findings must be submitted as soon as possible to the CRO/ sponsor . 
The SAE  forms must be faxed within 24  hours  for the attention of  
INC Research Drug Safety  
Fax No.  +1 877- 464-7787 
e-mail: INCdrugSafety@INCResearch.com  
The immediate SAE report will be made by the investigator within a very short period of time and under no circumstances should this exceed 24 hours following knowledge of the SAE.  
Although the infor mation required for completion of a SAE report form may not be available 
within the specified time period, an initial report should be submitted with the following information available.  
• Subject ID ( screening /randomization number)  
• The suspect product/form ulation – as blinded only the dose strength will be detailed  
• An event or outcome tha t can be identified as serious  
• The seriousness criterion  
• The causal assessment (note: this may changes  as more information is learned, however, an 
assessment MUST accompany the original report ) 
All SAE information must be recorded on an SAE form and sent within 24 hours or 1 business day of learning of the report to INC Drug Safety. Additional information received for a case (follow -up or corrections to the original case) need to be detailed on an SAE form and sent to 
INC Drug Safety . The SAE will be followed up until a final outcome and date are available. 
Instances of death, congenital abnormality, or an event that is of such clinical concern as to influence the overall assessment of safety, if brought to the attention of the investigator at any time after cessation of study drug administration and linked by the investigator to this study, should be report ed to the study monitor . 
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  68 of 97 
 
CONFIDENTIAL  The sponsor /CRO  will promptly notify all relevant investigators and the regulatory authorities of 
findings that could adversely affect the safety of subjects, impact on the conduct of the study or 
alter the IEC/IRB approval/ favorable opinion of the study. In addition, CRO/ sponsor  will 
expedite the reporting to all concerned investigators, to the IECs/IRBs, where required, and to the regulatory authorities of all adverse reactions that a re both serious and unexpected.  
Details of the procedures to be followed if a pregnancy occurs are provided in Section  8.3.4. 
Although pregnancy is not an SAE, and an elective abortion is not an SAE, any spontaneous abortion and/or any pregnancy that meets any regulatory serious criterion, or any pregnancy with an outcome for the pregnant person or the infant that meets regulatory serious criterion will be captured as an SAE.  
10.1.2.1.2 Unexpected Adverse Reactions  
Unexpected Adverse Reaction D efinition  
An unexpected adverse reaction is any untoward and unintended response that is related to the administration of the  study drug at any dose that is not consistent with the applicable product 
information (e .g. investigator s brochure for an unauthor ized investigational medicinal product  or 
summary of product characteristics for an author ized product).  
All suspected unexpected serious adverse reactions (SUSARs) will be the subject of expedited reporting. The sponsor /CRO  shall ensure that all relevant information about a SUSAR that is 
fatal or life -threatening is reported to the relevant competent authorities and IEC/IRB within 7 
days after knowledge by the sponsor  of such a case and that relevant follow up information is 
communicated within an additional 8 days . All other SUSARs will be reported to the relevant 
competent au thorities and IEC/IRB within 15  days after knowledge by the sponsor  of such a 
case. All investigators should follow up SUSARs until the event is resolved or until, in the opinion of the investigator, the event is stabil ized or determined to be chronic . Post study 
SUSARs that occur after the subject has completed the clinical study must be reported by t he 
investigator to the sponsor . 
Warnings and Precautions  
Safety Assessment to Exclude Obstructive Sleep Apnea  
Sodium oxybate, when given to subject s with obstructive sleep apnea  (OSA) will increase the 
risk of advancing sedation and respiratory depression. To support screening activities in ensuring subjects with OSA are detected and excluded as early as possible from the FT218 clinical study, a number of primary criteria will be  assessed at Visit 1 to rule out OSA. Specifically, this will 
include taking the subject’s neck circumference and documenting snoring patterns. These criteria will be assessed relative to ESS score, BMI, BP, age, and gender. A determination on eligibility to proceed through the screening period will be made relative to OSA risk. PIs will be trained on this at Site Initiation.  In the event that foll owing completion of the assessment  the risk  of OSA 
goes undetected, confirmation of the presence of OSA will be  detected on overnight PSG (AHI  ≥ 
15) at Week  3 in the screening and baseline period of the study. Where OSA is detected, the 
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  69 of 97 
 
CONFIDENTIAL  subject will be withdrawn from study. Include  any information relevant to safety ( i.e., known 
side effects or treatment of potential side effects).  
Safety Assessment of Suicidality  
Study subjects will be assessed at study screening for suicidality using the C -SSRS. At risk 
subjects will be withdrawn. Risk for the emergence of suicidality, using the C -SSRS, will be 
assessed at each st udy visit for the duration of the clinical study. Where risk is identified, study 
subjects will immediately be withdrawn from study. The PI will implement the most appropriate 
medical and psychological care pathway to ensure subject safety and recover. Where a subject is 
withdrawn for suicidality this will be clearly indicated as the reason for withdrawal on the withdrawal form and in source data.  
Safety Assessment for Abuse and Dependence  
Subjects with a history of drug abuse and/or dependence will be assessed at the screening  visit by 
the PI/ designee . Subjects with a known and discernable history of abuse and/or dependence will 
be excluded.  
Subjects will be assessed by the PI/designee for any signs and symptoms which may indicate an emergent abuse and dependence i .e. positive urine drug screen indicating concomitant use of 
contraindicated prescription drugs and/or illicit drug use, evidence or family report of concomitant use of alcohol with study drug product, suspicious claim(s) of lost product and looking for replacement study drug 
10.1.2.2 Clinical Laboratory Evaluation  
The hem atology and biochemistry  laboratory analyses will be performed at a central laboratory 
(ACM Global Central Laboratory, Rochester, US ). Reference ranges will be supplied and used 
by the investigator to assess the laboratory data for clinical significance and pathological 
changes . The following laboratory safety tests will be performed:  
Hem atology 
Hem oglobin, hem atocri t, white blood cell count  (total and differential ), red blood cell count, 
platelet count, mean cell volume , mean cell hem oglobin, and mean cell hemoglobin 
concentration  
Bioc hemistry  
Creatinine, blood urea nitrogen, aspartate transferase, alanine transferase , gamma 
glutamyltransferase , alkalin e phosphatase, total bilirubin, albumin, globulin, total protein, 
sodium, potassium, chloride, bicarbonate,  estimated glomerular filtration rate , carbon dioxide , 
glucose, total cholesterol, tri glycerides,  and creatine phosphokinase . 
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  70 of 97 
 
CONFIDENTIAL  Urinalysis  
pH, glucose, ketones, blood, and protein by dipstick test at the  central laboratory. If  any of these 
parameters gives a positive result, a quantitative result will be transmitted.  
10.1.2.2.1 Other L aboratory V ariables  
Drugs of Abuse Screening: Urine drug screen will comprise cocaine, benzodiazepines, 
cannabis , opiates, and barbiturates.  
Serology:  Hepatitis B surface antigen, and hepatitis C antibody  
Pregnancy : serum β -human chorionic gonadotropin test will be performed at screening  (Visit 1) , 
urine β - human chorionic gonadotropin test at all other visits.  
10.1.2.3 Vital Signs  
Vital signs consist ing of systolic and diastolic BP  and heart rate will be recorded after at least 
5 minutes in the sitting position . 
10.1.2.4 Physical Examination  
A complete physical examination including weight and evaluation of main body systems/regions, including: skin and mucous, ears/nose/throat, pulmonary, cardiac, GI, and neurological systems.  
In case of abnormality, a comment will be recorded in the eCRF and subjects medical notes. Any deterioration in condition wi ll be reported as an AE.  
10.1.2.5 Electrocardiogram  
Twelve- lead ECGs will be recorded after at least 5 minutes in the s upine  position.  
Each ECG consists of a 10 second recording of the 12 leads simultaneously, leading to a 12- lead 
ECG (25 mm/s, 10mm/mV) printout with HR, PR, QRS, QT, QTc automatic correction evaluation, including date, time, initials and number of the subject, signature of the research physician, and at least 3 complexes for each lead. The ECG interpretation and values will be recorded in  the eCRF.  
10.1.3 Appropriateness of Measurements  
The efficacy and safety assessments planned for this study are widely used and generally recognized as reliable, accurate, and relevant to the dis ease condition.  
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  71 of 97 
 
CONFIDENTIAL  11 STATIS TICAL M ETHODS  
Two subject  populations, one with both narcolepsy symptoms and one with EDS will be studied 
in a single parallel group dose-escalation design. The treatments are placebo and increasing 
doses of the test drug, FT218. Two primary outcome measures, MWT and CGI quantify the treatment effect on EDS and the NCA is the primary outcome measure for cataplexy.  
11.1 Statistical and Analytical Plans 
The material in this section provides the basis of the s tatistical analysis plan (SAP) for this study. 
A complete SAP has been prepared to accompany this protocol for submission to the FDA for 
the Special Protocol Assessment. Details are provided therein.  
11.2 Definition of the Analysis Populations 
The target population is individuals in need of treatment of EDS and cataplexy in subjects with narcolepsy. The full analysis population for efficacy is the intent- to-treat (ITT) population 
including all randomized subjects with at least one efficacy measurement after receiving  the 6 .0 
g dose (whether FT218 or placebo). 
11.2.1 Determination of Sample Size 
Estimation of sample size to achieve a desired power depends on the number and nature of the 
hypothesis testing paradigm and assumptions about the magnitude of the underlying effects . In 
this study, hypothesis testing will proceed in the following order. First MWT and CGI will be examined for statistical significance in the full sample including both NT1 and NT2 subjects for the 9 g dose . If significant, NCA for the same dose will be tested in NT1 subjects. If the first test 
fails, the data from this dose is not able to reject the null hypothesis of equality to placebo. If the first test is significant, but the second fails, the dose has been demonstrated to be superior to placebo for EDS treatment, but not for cataplexy. If both tests are statistically significant, the dose has been shown to be effect ive for both EDS and cataplexy treatment. The same sequence 
of testing will be followed for the 7.5 g and then the 6.0 g  dose in a hierarchical manner .  
Each outcome measure for the 9.0 g, 7.5 g and 6.0 g dose  will be tested at the 2 -sided α  level of 
0.05. 
11.2.2 Randomization and Blinding  

Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  72 of 97 
 
CONFIDENTIAL  11.2.3 Interim Analysi s and Unblinding  
There are no planned interim analys es. Other than individual subjects being unblinded for safety 
issues, the database will remain blinded until after the database is locked.  
11.2.4 Data and Safety Monitoring Board  
An independent Data and Safety Monitoring Board (DSMB) will be appointed to review and 
assess study conduct and safety for the duration of the clinical study. 
11.3 Analysis Sets  
The ITT and per protocol (PP) populations form the bases for the evaluation of effi cacy. The 
safety (S) population forms the basis for the evaluation of safety  
11.3.1 Intent -to-Treat (ITT) Population  
The ITT population includes all randomized subjects with at least one efficacy measurement 
after receiving the 6 .0 g dose (whether FT218 or placebo). A valid diary measurement is defined 
to include at least 3 days of entries  per week . Diary measurements with fewer days will be 
treated as missing, and if there are no other measurements, will not qualify the subject for the ITT population. Subjects wi ll be assigned to treatment arms  in the analysis as randomized.  
11.3.2 Per Protocol (PP) Population  
The PP population includes all subjects in the ITT population reduced by those who failed to follow the protocol with respect to protocol deviations . These are, i nclusion or exclusion criteria 
not satisfied ( Section 8.3.2 and Section 8.3.3); deviations related to study drug administration, 
deviations to the schedule of visits and procedures , or deviations related to non-permitted 
concomitant medications ( Section 8.4.8.1). Subjects will be assigned to treatment arms  as 
randomi zed. 
11.3.2.1 Safety (S) Population  
The S population includes all subjects that receive at l east one dose of study drug. Subjects will 
be assigned to treatment arms  based on the treatment actually administered  (FT218 if active drug 
was administered at any time, placebo otherwise) . 
11.4 Description of Statistical Analysis  
The formal statistical analysis and specific dose/placebo contrasts will be based on a mixed -
effects repeated measures model. Descriptive statistics characterizing the study population and the observed outcomes will be produced.  
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  73 of 97 
 
CONFIDENTIAL  11.4.1 General Considerations  
All statistical tests will be performed using a 2- tailed 5% overall significance level, unless 
otherwise specified. Descriptive statistics will be provided by treatment arm and as a summary 
across both treatment arms.  
11.4.2 Use of Analysis Sets 
For the primary statistical analysis of efficacy endpoints, the ITT will be used; a supportive analysis will be carried out on the PP population unless it is essentially the same as the ITT population, if the difference in sample sizes is less than 10%. All safety endpoints analysis will be conducted on the S population. 
11.4.3 Analysis of Subgroups 
The primary efficacy analyses of EDS will be performed on the ITT population. The primary 
efficacy analyses for cataplexy will be performed on the NT1 subgroup of the ITT population. 
11.5 Subject Disposition  
The number of subjects within each treatment arm of each analysis population will be 
summarized. The number of subjects entering each period of the study will be tabulated along with the number of subjects who withdraw. The timing of withdrawal and reasons for withdrawal (Section 8.3.4) will be summarized  by treatment arm for each period of the study and 
summarized over all p eriods in the randomized stage. 
11.6 Demographic and Other Baseline Characteristics  
Subject demographics will be presented by treatment arm and for the total study. Baseline will be defined as the last measurement before randomization. Initial data at screening will also be reported for all screened subjects.  
Cases for which the entry cr iteria or other protocol requirements were violated will be identified 
and their baseline characteristics will be summarized.  
11.7 Medical History  
Medical history data will consist of significant conditions or diseases recorded during the 
screening process. Dat a will be tabulated using the Medical Dictionary for Regulatory Activities 
(MedDRA ) primary system organ class (SOC) and preferred term for subjects in the S 
population.  

Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  75 of 97 
 
CONFIDENTIAL  hypotheses for EDS, both MWT and CGI will be examined for st atistical significance for the 9.0 
g dose using the data collected during Period 3c(i) , and 3c(ii). If both tests are significant, NCA 
for the same dose will be tested. If the first test fails (either MWT or CGI not significant), the 
data for the 9.0 g dose was not able to reject the null hypothesis of equality to placebo for either symptom. If the first test is significant (both MWT and CGI significant) but the second test (NCA) fails, the dose has been demonstrated to exceed placebo for EDS treatment but not for cataplexy. If both tests are statistically significant, the dose has been shown to be effective for EDS and cataplexy.  
If the 9.0 g dose demonstrates efficacy for both EDS and cataplexy, t he same sequence of testing 
will be followed for the 7.5 g dose using the data collected during Period 3b(i) and 3b(ii). If the 
7.5 g dose demonstrates efficacy for both EDS and cataplexy, the same sequence of testing will be followed for the 6 g dose using the data collected during Period 3a.  
 Each dose will be tested at the 2 -sided alpha level of 0.05. Efficacy tests for MWT and for CGI 
within a dose need not be adjusted, since both are required for demonstrating efficacy for EDS at 
that dose. Efficacy tests for NCA within a dose for demonstrating efficacy for c ataplexy also 
need not be adjusted because the test is reached via a step down procedure. At each step, rejection terminates all subsequent hypothesis tests, which will be deemed to be non-significant. A strictly exploratory analysis examining secondary/exploratory endpoints is also proposed to provide evidence of consistency. The t ype I error rate for these endpoints will all be tested at the 
α level of 0.05. 
Note: the testing of the efficacy of the 6 .0 g dose is intended to address the question of 
identifying the minimally effective dose. If the 9.0 g dose and then  the 7.5 g dose is effective on the primary outcome variables, hypothesis tests on the efficacy of the 6.0 g dose will be carried out. 

Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  76 of 97 
 
CONFIDENTIAL  11.10
 Safety Analysis 
Safety evaluation will be conducted on the S population and using the same evaluation period as 
for efficacy analysis.  
Safety will be evaluated based on reports of AEs  either spontaneously reported or observed in 
clinical laboratory analyses. They will be coded according to the MedDRA . 
Adverse events will be summariz ed based on number and percentages of subjects with any AEs , 
SAEs , and permanent withdrawal from the study. Adverse events will also be tabulated by SOC  
and preferred term.  
11.10.1.1 Laboratory Data 
Laborato ry data will be summarized in terms of the proportions of subject s with clinically 
relevant abnormalities using normal ranges. Shift tables will tabulate baseline to most extreme post baseline value. Summary statistics of raw data and change from baseline values , including 
means, medians, standard deviations, and ranges will be produced. Analyses will include all subjects in the S population who have had at least one laboratory test performed after the first study drug administration with an available baseline laboratory value. Baseline values will be measured as the last available measure before taking study drug.  
11.11 Data and Safety Monitoring Board 
An independent DSMB will be appointed to review and assess study conduct and safety for the duration of the clinical study. 
This clinical study will be conducted in a double-blind manner. The DSMB comprises 
independent experts who will advise the sponsor and study investigator on matters relating to the safety and conduct of the clinical study. The DSMB will make recommendations to the sponsor and clinical study investigators about the continuation, modification or termination of the clinical study. To achieve this aim the appointed independent DSMB will periodically review and evaluate accumulated study data as they relate to s tudy subject safety, study progress and 
conduct. 
The DSMB will be governed by a charter which will define the deliberative processes of the 
group, including event triggers which would necessitate an unscheduled review, stopping rules, unblinding, and any voting procedures to initiate any data review. Confidentiality of internal discussions and activities will be upheld with a systematic reporting process to sponsor and dissemination process to all study investigators, IEC/IRB s and regulatory authorities as 
appropriate. The membership of the DSMB will reflect necessary clinical, scientific, and related disciplines necessary to interpret data from the clinical study to allow for full evaluation of study 

Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  77 of 97 
 
CONFIDENTIAL  subject safety. The DSMB will be blinded to treatment ass ignment with the exception of the 
unblinded biostatistician.  
The composition of the DSMB will be laid out in the charter. No member of the DSMB should 
have direct involvement in the conduct of the study. In addition, no member will have financial, propriet ary, professional, or other i nterests in Flamel T echnologies that may affect impartial, 
independent decision- making by the DSMB.  
11.12 Central Scoring Laboratory  
At Visit 2 (Week - 1, Day 7) a complete assessment for baseline efficacy parameters including an 
overnight baseline PSG and next -day MWT  will be performed , after which a central scoring 
laboratory ( Clinilabs, Inc New York, US ) will confirm the eligibility of each subject. The central 
scoring lab will resp ond with its assessment within 2  days of receipt of  PSG and MWT 
assessments.  
The central scoring laboratory will have the necessary expertise and qualification to conduct 
PSG and MWT scoring.  
11.13 Protocol Deviations  
Protocol deviations will consist of: inclusion or exclus ion criteria not satisfied ( Section 8.3.2 and 
Section 8.3.3); deviations related to study drug administration, deviations to the schedule of visits and procedures, or deviations related to nonpermitted concomitant medications ( Section 
8.4.8.1).  
12 QUALITY ASSURANCE AND QUAL ITY CONTROL  
12.1 Audit and Inspection  
Study cen ters and study documentation may be subject to quality a ssurance audit during the 
course of the study by the sponsor  or its nominated representative . In addition, inspections may 
be conducted by regulatory authorities  at their discretion.  
12.2 Monitoring  
Data for each subject will be recorded on an eCRF . Data collection must be completed for each 
subject who signs an informed consent form ( ICF) and is administered study drug. 
In accordance with cGCP an d ICH guidelines, the study monitor will carry out source document 
verification at regular intervals to ensure that the data collected in the eCRF are accurate and 
reliable .  
The investigator must permit the monitor, the IEC /IRB , the sponsor ’s internal aud itors, and 
representatives from regulatory authorities direct access to all study -related documents and 
pertinent hospital or medical records for confirmation of data contained within the e CRFs . 
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  78 of 97 
 
CONFIDENTIAL  12.3 Data Management and Coding  
The CRO will be responsible for ac tivities associated with the data management of this study . 
This will include setting up a relevant database and data transfer mechanisms, along with 
appropriate validation of data and resolution of queries . Data generated within this clinical study 
will b e handled according to the relevant standard operating procedures  of the data management 
and biostatistics departments of  the CRO . 
Study centers  will enter data directly into an electronic data capture (EDC) system by completing 
the e CRF via a secure inter net connection . Data entered into the e CRF must be verifiable against 
source documents at the study center . Data to be recorded directly on the eCRF will be identified 
and the e CRF will be considered the source document . Any changes to the data entered into the 
EDC system will be recorded in the audit trail and will be FDA CFR  21 Part  11 compliant. 
Medical coding will use MedDRA for concomitant diseases and AEs and WHO  Drug Dictionary 
for medications.  
Missing or inconsiste nt data will be queried in writing to the investigator for clarification . 
Subsequent modifications to t he database will be documented.  
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  79 of 97 
 
CONFIDENTIAL  13 RECORDS AND SUPPLIES  
13.1 Financing and Insurance  
Financing and insurance of this study will be outlined in a se parate agreement between the CRO  
and the sponsor . 
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  80 of 97 
 
CONFIDENTIAL  14 ETHICS  
14.1 Independent Ethics Committee or Institutional Review Board  
Before initiation of the study at each study cen ter, the protocol, the ICF, other written material 
given to the subjects, and any other relevant study documentation will be submitted to the 
appropriate IEC/ IRB. Written approval of the study and all relevant study information must be 
obtained before the study cen ter can be initiated or the study drug is released to the investigator . 
Any necessary extensions or renewals of IEC/IRB approval must be obtained for changes to the 
study such as amendments to  the protocol, the ICF or other study documentation. The written 
approval of the IEC/IRB together with the approved ICF must be filed in the study files. 
The investigator will report promptly to the IEC/IRB any new information that may adversely 
affect the safety of the subjects or the conduct of the study. The investigator will submit written 
summaries of the study status to the IEC/IRB as  required. On completion of the study, the 
IEC/IRB will be not ified that the study has ended.  
14.2 Regulatory Authorities  
Relevant study documentation will be submitted to the r egulatory authorities of the participating 
countries, according to local/national re quirements, for review and approval before the beginning 
of the study. On completion of the study, the r egulatory a uthorities will be notified that the study 
has ended.  
14.3 Ethical Conduct of the Study  
The investigator(s) and all parties involved in this study should conduct the study in adherence to 
the ethical principles based on the Declaration of Helsinki, GCP, ICH guidelines, and the applicable national and local laws and regulatory requirements.  
14.4 Informed  Consent  and Assent  
The process of obtaining informe d consent must be in accordance with applicable regulatory 
requirement(s) and must adhere to GCP . 
Young adults who have not reached the age of majority i .e. those who are 16 or 17 years of age, 
who meet the enro llment criteria are eligible to participate in this clinical study. The basic 
requirement of 21 Code of Federal Regulations (CFR) 50.20 applies, that is, 1) consent from their legally authorized representative must be obtained and 2) the assent of the young adult must be obtained. In obtaining assent, it must be determined by the PI that the young adult is of both intellectual and emotional ability to comprehend study requirements and implications. 
The investigator is responsible for ensuring that no subject undergoes any study- related  
examination or activity before that subject has given written informed consent to participate in 
the study. 
The investigator or designated personnel will inform the subject of the objectives, methods, 
anticipated benefits and potential risks and inconveni ences of the study . The subject should be 
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  81 of 97 
 
CONFIDENTIAL  given every opportunity to ask for clarification of any points s/ he does not understand and, if 
necessary, ask for more information. At the end of the interview, the subject will be given ample 
time to consider the  study. Subjects will be required to sign and date the ICF . After signatures 
are obtained, the ICF will be kept and archived by the investigator in the investigator’s study file . 
A signed and dated copy of the subject ICF will be provided to the subject or  their authorized 
representative.  
It should be emphas ized that the subject may  refuse to enter the study or to withdraw from the 
study at any time, without consequences for their further care or penalty or loss of benefits to which the subject is otherwise  entitled . Subjects who refuse to give or who withdraw written 
informed consent should not be included or continue in the study. 
If new information becomes available that may be relevant to the subject’s willingness to 
continue participation in the study, a new ICF will be approved by the IEC(s)/IRB(s) (and regulatory a uthorities , if required). The study subjects will be informed about this new 
information and reconsent will be obtained. 
14.5 Subject Confidentiality  
Monitors, auditors, and other authorized a gents of the sponsor  and/or its designee, the 
IEC(s)/IRB(s) approving this research, and the US FDA , as well as that of any other applicable 
agency(ies), will be granted direct access to the study subjects’ original medical records for 
verification of clinical study procedures and/or data, without violating the confidentiality of the subjects to the extent permitted by the law and regulations . In any presentations of the results of 
this study or in publications, the subjects’ identity will remain confidential.  
All personal data collected and processed for the purposes of this study should be managed by the investigator and his/her staff with adequate precautions to ensure confidentiality of those data, and in accordance with the Health Insurance Portability and Accountability Act , applicable 
to national and/or local laws and regulations on per sonal data protection. 
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  82 of 97 
 
CONFIDENTIAL  15 REPORTING AND PUBLICATION, INCLUDING ARCHIVING  
Essential documents are those documents that individually and collectively permit evaluation of 
the study and quality of the data produced. After completion of the study (end of study defined as 
the date of the last visit of the last subject) , all documents and data relating to the study will be 
kept in an orderly manner by the investigator in a secure  study file . This file will be available for 
inspection by the sponsor  or its representatives . Essential documents should be retained for 2 
years after the final marketing approval in an ICH region or for at least 2 years since the discontinuation of clini cal development of the investigational product . It is the responsibility of 
the sponsor  to inform the study cen ter when these documents no longer need to be retained. The 
investigator must contact the sponsor  before destroying any study- related  documentati on. In 
addition, all subject medical records and other source documentation will be kept for the maximum time permitted by the hospital, institution , or medical practice.  
The sponsor  must review and approve any results of the study or abstracts for professional 
meetings prepared by the investigator(s) . Published data must not compromise  the objectives of 
the study. Data from individua l study cen ters in multicen ter studies mu st not be published 
separately.  
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  83 of 97 
 
CONFIDENTIAL  16 REFERENCES  
 Wake Up Narcolepsy Inc. Patient -focused Narcolepsy Survey: Interim Analysis as of September 16, 
2013; http://www.unitenarcolepsy.org/wp- content/uploads/Interim -Survey- Analysis -v1.pdf. 
Accessed May 10, 2015.  
 Jennum P, Ibsen R, Knudsen S, Kjellberg J. Comorbidity and mortality of narcolepsy: a controlled 
retro - and prospective national study. Sleep. 2013;36: 835-840. 
 Ohayon MM. Narcolepsy is complicated by high medical and psychiatric comorbidities: a 
comparison with the ge neral population. Sleep Med. 2013;14:488- 492. 
 Ohayon MM, Black J, Lai C, Eller M, Guinta D, Bhattacharyya A. Increased mortality in narcole psy. 
Sleep. 2014;37:439- 444. 
 Ervik S, Abdelnoor M, Heier MS, Ramberg M, Strand G. Health -related quality of life in narcolepsy. 
Acta Neurol Scand. 2006;114:198- 204. 
 Broughton RJ, Guberman A, Roberts J. Comparison of the psychosocial effects of epilepsy and  
narcolepsy/cataplexy: a controlled study. Epilepsia. 1984;25:423- 433. 
 Jennum P, Ibsen R, Petersen ER, Knudsen S, Kjellberg J. Health, social, and economic consequences of narcolepsy: a controlled national study evaluating the societal effect on patients a nd their partners. 
Sleep Med. 2012;13:1086- 1093.  
 Dodel R, Peter H, Walbert T, et al. The socioeconomic impact of narcolepsy. Sleep. 2004;27:1123-1128.  
 Jennum P, Knudsen S, Kjellberg J. The economic consequences of narcolepsy. J Clin Sleep Med. 
2009;5:240- 245. 
 Black J, Reaven NL, Funk SE, et al. The B urden of N arcolepsy Disease (BOND) study: health -care 
utilization a nd cost findings. Sleep Med. 2014;15:522- 529.  
 American Academy of Sleep Medicine. International Classification of Sleep Disorders. 3rd ed. 
Darien, Ill: American Academy of Sleep Medicine; 2014.  
 Longstreth WT Jr, Koepsell TD, Ton TG, Hendrickson AF, van Belle G . The epidemiology of 
narcolepsy. Sleep 2007; 30:13- 26. 
 Nohynek H, Jokinen J, Partinen M, et al. AS03 adjuvant AH1N1 vaccine associated wit h an abrupt 
increase in the incidence of childhood narcolepsy in Finland. PLoS One . 2012; 7:e33536.  
 Partinen M, Saarenpää- Heikkilä O, Ilveskoski I, et al. Increased incidence and clinical picture of 
childhood narcolepsy following the 2009 H1N1 pandemic vac cination campaign in Finland. PLoS 
One. 2012;7:e33723.  
 Mignot E, Lin L, Rogers W,  et al. C omplex HLA -DR and -DQ interactions confer risk of narcolepsy -
cataplexy in three ethnic groups. Am J Hum Genet. 2001; 68: 686- 699. 
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  84 of 97 
 
CONFIDENTIAL  
 Hor H, Kutalik Z, Dauvilliers Y, et al. Genome -wide association study identifies new HLA class II 
haplotypes strongly protective against narcolepsy. Nat Genet. 2010; 42:786 789.  
 Kornum BR, Kawashima M, Faraco J et al. Common variants in P2RY11 are associated with 
narcolepsy.  Nat Genet. 2011; 43:66- 71. 
 Aran A, Lin L, Nevsimalova S, et al. Elevated anti -streptococcal antibodies in patients with recent 
narcolepsy onset. Sleep . 2009; 32:979- 983. 
 Cvetkovic -Lopes V, Bayer L, Dorsaz S, et al. Elevated Tribbles homolog 2- specific antib ody levels 
in narcolepsy patients. J Clin Invest. 2010 ;120: 713-719. 
 Mitler MM. Evaluation of treatment with stimulants in narcolepsy. Sleep. 1994;17(8 Suppl):S103-
S106. 
 Roth T, Dauvilliers Y, Mignot E, et al. Disrupted nighttime sleep in narcolepsy. J Clin  Sleep Med. 
2013; 9:955- 65. 
 Sangal RB, Thomas L, Mitler MM. Disorders of excessive sleepiness. Treatment improves ability to 
stay awake but does not reduce sleepiness. Chest . 1992;102:699- 703. 
 Nishino S. Clinical and neurobiological aspects of narcolepsy . Sleep Med . 2007;8:373- 399.  
 Doghramji K, Mitler MM, Sangal RB, et al. A normative study of the maintenance of wakefulness 
test (MWT). Electroencephalogr Clin Neurophysiol. 1997; 103:554- 562. 
 
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  85 of 97 
 
CONFIDENTIAL  17 APPENDICES  
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  86 of 97 
 
CONFIDENTIAL  17.1 Investigator Signature Page  
Protocol Title:  A Double -blind, Randomized, Placebo Controlled, Two Arm Multi -center 
Study  to Assess the Efficacy and Safety of a Once Nightly Formulation of 
Sodium Oxybate for Extended -Release Oral Suspension  (FT218) for the 
Treatment of Excessive Daytime Sleepiness and Cataplexy in Subject s 
with Narcolepsy  
Protocol Number:  CLFT218 -1501  
Confidentiality and cGCP Compliance Statement  
I, the undersigned, have reviewed this protocol  (and amendments) , including a ppendices , and I 
will conduct the study as described in compliance with this protocol  (and amendments) , GCP, 
and relevant ICH g uidelines. 
Once the protocol has been approved by the IEC/IRB, I will not modify this protocol without 
obtaining prior approval of Flamel Technologies  and of the IEC/IRB. I will submit the protocol 
amendments and/or any ICF modifications to Flamel Technologies  and IEC/IRB, and approval 
will be obtained before any amendment s are implemented.  
I understand that all information obtained during the conduct of the study with regard to the 
subjects’ state of health will be regarded as confidential . No subject s’ names will be disclosed . 
All subject s will be identified by assigned numbers on all e CRF s, laboratory samples , or source 
documents forwarded to the sponsor . Clinical information may be reviewed by the sponsor  or its 
agents or regulatory agencies . Agreement must be obtained from the subject before disclosure of 
subjec t information to a third party.  
Information developed in this clinical study may be disclosed by Flamel Technologies , to other 
clinical investigators,  regulatory agencies, or other health authority or government agencies as 
required.  
   
Investigator Signature   Date  
   
Printed Name    
   
Institution    
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  87 of 97 
 
CONFIDENTIAL  17.2 Study Drug Kit Dispensing  
The table below details the specifications of drug supply quantities for each week of dosing for 
the duration of the study.  
Dosing Week 
& Type  Dose 
Strength  Sachet Strength 
Dispensing  Efficacy Assessment Requirement  Drug Administration  
Specifications  
Study Period 3a  – Dose Titration  
Week 1  
 4.5 g  4.5 g  
(1× 4.5 g/night ) 
+ dosing cup  Not for this week  Subject self - administration ×  
7 nights  
Week 2  
 6 g 6 g  
(2 × 3.0 g/night)  Not for this week  Subject self -administration ×  
7 nights  
Week 3  
 6 g 6 g  
(2 × 3 .0 g/night)  Yes: on night 7 of Week 3  
Full efficacy assessment –  
overnight PSG and next -day 
MWT  Subject self -administration ×  
6 nights.  
Night 7 Drug dispensed at clinic in 
advance of overnight PSG.  
Study Period 3b(i) - Dose Titration  
Week 4  7.5 g  7.5 g  
(1 × 3 g/night,  
1 × 4.5 g/night)  Not for this week  Subject self -adminis tration ×  
7 nights  
Week 5  
 7.5 g  7.5 g  
(1 × 3 g/night,  
1 × 4.5 g/night)  Partial Efficacy Assessment  Subject self -administration ×  
7 nights  
Study Period 3b(ii) – Dose Titration  
Week 6  7.5 g  7.5 g  
(1 × 3 g/night,  
1 × 4.5 g/night)  Not for this week  Subject se lf -administration ×  
7 nights  
Week 7  
 7.5 g  7.5 g  
(1 × 3 g/night,  
1 × 4.5 g/night)  Not for this week  Subject self -administration ×  
7 nights  
Week 8  
 7.5 g  7.5 g  
(1 × 3 g/night,  
1 × 4.5 g/night)  Yes: on n ight 7 of Week 8 
Full efficacy assessment -overnight 
PSG and next -day MWT  Subject self -administration ×  
6 nights.  
Night 7 Drug dispensed at clinic in 
advance of overnight PSG.  
Study Period 3c(i) – Stabilization  
Week 9  
 9.0 g 9.0 g  
(2 × 4.5 g/night)  Not for this week  Subject self -administration ×  
7 nights  
Week 1 0 
 9.0 g 9.0 g  
(2 × 4.5 g/night)  Partial Efficacy Assessment  Subject self -administration ×  
7 nights  
Study Period 3c(ii) – Stabilization  
Week 11   
 9.0 g 9.0 g  
(2 × 4.5 g/night)  Not for this week  Subject self -administration ×  
7 nights  
Week 12  
 9.0 g 9.0 g  
(2 × 4.5 g/night)  Not for this week  Subject self -administration ×  
7 nights  
Week 13  
 9.0 g 9.0 g  
(2 × 4.5 g/night)  Yes: on n ight 7 of Week 1 3 
Full efficacy assessment - overnight 
PSG and next -day MWT  Subject self -administration ×  
6 nights.  
Night 7 Drug dispensed at clinic in 
advance of overnight PSG.  
 
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  88 of 97 
 
CONFIDENTIAL  

Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  90 of 97 
 
CONFIDENTIAL  

Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  92 of 97 
 
CONFIDENTIAL  17.4 Columbia -Suicide Severity Rating Scale (C -SSRS) – Since Last Visit Version  

Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  93 of 97 
 
CONFIDENTIAL  17.5 Columbia -Suicide Severity Rating Scale (C -SSRS) – Baseline/Screening Version  
 

Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  94 of 97 
 
CONFIDENTIAL  

Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  95 of 97 
 
CONFIDENTIAL   
  

Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  96 of 97 
 
CONFIDENTIAL  17.6 CGI -Severity (CGI -S) / CGI -Improvement (CGI -I)  
 
CGI-Severity (CGI -S) 
Considering your total clinical experience with this patient population, how sleepy  is the patient at 
this time?  
 
☐ 1. Normal, not at all sleepy  
 
☐ 2. Borderline sleepy  
 
☐ 3. Mildly sleepy  
 ☐ 
4. Moderately sleepy  
 
☐ 5. Markedly sleepy  
 ☐
 6. Severely sleepy  
 
☐ 7. Among the most extremely sleepy  patients 
 
 
CGI-Improvement (CGI -I) 
 
Compared to the patient’s condition at BASELINE, this patient’s condition is:  
 
☐ 1. Very much improved  
 
☐ 2. Much improved  
 
☐ 3. Minimally improved  
 ☐ 
4. No change from baseline  
 
☐ 5. Minimally worse  
 ☐
 6. Much worse  
 
☐ 7. Very much worse  
 
 
  
 
 
 
Flamel Technologies     01 August 2019  
CLFT218 -1501   Final v5.0  Page  97 of 97 
 
CONFIDENTIAL  17.7 Epworth Sleepiness Scale  
 
